US20050004109A1 - Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia - Google Patents

Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia Download PDF

Info

Publication number
US20050004109A1
US20050004109A1 US10/902,249 US90224904A US2005004109A1 US 20050004109 A1 US20050004109 A1 US 20050004109A1 US 90224904 A US90224904 A US 90224904A US 2005004109 A1 US2005004109 A1 US 2005004109A1
Authority
US
United States
Prior art keywords
groups
group
meo
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/902,249
Inventor
Shinichi Kurakata
Masaharu Hanai
Saori Kanai
Tomio Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to US10/902,249 priority Critical patent/US20050004109A1/en
Publication of US20050004109A1 publication Critical patent/US20050004109A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47G—HOUSEHOLD OR TABLE EQUIPMENT
    • A47G7/00—Flower holders or the like
    • A47G7/02—Devices for supporting flower-pots or cut flowers
    • A47G7/04—Flower tables; Stands or hangers, e.g. baskets, for flowers
    • A47G7/044—Hanging flower-pot holders, e.g. mounted on walls, balcony fences or the like
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G5/00—Floral handling
    • A01G5/04—Mountings for wreaths, or the like; Racks or holders for flowers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
    • G09F23/00—Advertising on or in specific articles, e.g. ashtrays, letter-boxes

Definitions

  • the present invention relates to the use of certain compounds, specifically cyclooxygenase-2 inhibitors (hereinafter referred to as “COX-2 inhibitors”) for the treatment and prevention of tumors and tumor-related disorders and cachexia.
  • COX-2 inhibitors specifically cyclooxygenase-2 inhibitors
  • Cachexia is a systemic disease of which the cardinal symptoms are progressive weight loss, anemia, edema, loss of appetite and so forth. It may occur as a side-effect of certain chronic diseases, such as malignant tumors, tuberculosis, diabetes, blood diseases, endocrine diseases, infections and acquired immune deficiency syndrome.
  • malignant tumors such as malignant tumors, tuberculosis, diabetes, blood diseases, endocrine diseases, infections and acquired immune deficiency syndrome.
  • cachexia occurs as a result of the presence of a malignant tumor, even if the administration of antitumor drugs to the patient with malignant tumor is effective and antitumor effects are experienced, there is normally no improvement in the cachexia because of adverse effects such as the myelotoxicity which may be caused by the antitumor drug.
  • Nutritional supplements are often given in order to treat the symptoms of cachexia. This, however, often enhances the progress of the malignant tumor, and may shorten the survival time of the patient.
  • the compounds of formula (I) or (II), shown below, which, with certain other compounds, are the active ingredients of the compositions of the present invention, are known to inhibit selectively cyclooxygenase-2 (COX-2). They are also known to inhibit the production of inflammatory cytokines (particularly IL-1 and TNF- ⁇ ), to inhibit the production of leukotrienes particularly LTB 4 ), to inhibit bone resorption, and to have analgesic, anti-inflammatory and anti-pyretic effects (European Patent Publication No. 799 823A).
  • NSAIDS non-steroidal anti-inflammatory drugs, which are COX-1 and COX-2 inhibitors
  • COX-1 and COX-2 inhibitors COX-1 and COX-2 inhibitors
  • the experimental system used is not a model for an established colon cancer, and the compounds are only able to prevent the occurrence of polyposis in the preliminary stage of colon cancer.
  • colon cancer cell line in which growth inhibitory effects against human colon cancer cell lines have been observed is a cell line that expresses cyclooxygenase-2 (human colon cancer cell line HCA-7), and it has been disclosed that colon cancer cell lines that do not exhibit tumor growth inhibitory activity (HCT-116) in vitro do not exhibit tumor growth inhibitory effects in vivo.
  • HCT-116 tumor growth inhibitory activity
  • COX-2 inhibitor-induced tumor growth inhibitory effects on colon cancer depends on the sensitivity of the colon cancer cell lines used against COX-2 inhibitor-induced cell growth inhibitory activity in vitro.
  • the present invention provides a method for the treatment or prevention of cachexia in a mammal, which may be human, in need of such treatment or prevention, which method comprises administering to said mammal an effective amount of an active compound selected from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV): wherein
  • the invention further provides a method for the treatment or prevention of tumor-related disorders in a mammal, which may be human, in need of such treatment or prevention, which method comprises administering to said mammal an effective amount of an active compound selected from the group consisting of compounds of formula (I) and (II), defined above.
  • Preferred classes of compounds of the present invention are those compounds of formula (I) and (II) in which:
  • Said substituents ⁇ 1 are selected from the group consisting of halogen atoms, lower alkoxy groups and lower alkylthio groups.
  • Said substituents ⁇ 2 are selected from the group consisting of hydroxy groups, halogen atoms and lower alkoxy groups.
  • Said substituents ⁇ 1 are selected from the group consisting of lower alkyl groups, mercapto groups, alkanoylthio groups, lower alkyl groups having at least one substituent selected from the group consisting of substituents ⁇ 1 , lower haloalkoxy groups and lower alkylenedioxy groups.
  • Said substituents ⁇ 2 are selected from the group consisting of lower alkyl groups, mercapto groups, alkanoylthio groups, lower alkyl groups substituted with a halogen atom, lower haloalkoxy groups and lower alkylenedioxy groups.
  • Said substituents ⁇ 3 are selected from the group consisting of lower alkyl groups, lower alkyl groups having at least one substituent selected from the group consisting of substituents a and cycloalkyloxy groups.
  • Said substituents ⁇ 4 are selected from the group consisting of lower alkyl groups, lower alkyl groups substituted with a halogen atom and cycloalkyloxy groups.
  • the halogen atom is preferably a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom, a chlorine atom or a bromine atom.
  • R, R 1 , R 3 , R 4 , substituent ⁇ , substituent ⁇ 1 , substituent ⁇ 2 , substituent ⁇ 3 or substituent ⁇ 4 represents a lower alkyl group
  • R 3 , R 4 , substituent ⁇ , substituent ⁇ 1 or substituent ⁇ 3 represents a lower alkyl group having at least one substituent selected from the group consisting of substituents ⁇ , or substituent ⁇ 2 or substituent ⁇ 4 represents a lower alkyl group substituted with a halogen atom
  • the alkyl group or alkyl part of the substituted group may be a straight or branched chain alkyl group having from 1 to 6 carbon atoms, and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropy
  • the straight or branched chain alkyl groups having from 1 to 4 carbon atoms, more preferably the methyl and ethyl groups.
  • the lower alkyl group is particularly preferably the methyl group.
  • substituent ⁇ represents an alkanoyloxy group, or substituent ⁇ , substituent ⁇ 1 or substituent ⁇ 2 represents an alkanoylthio group
  • the alkanoyl part of these groups may be, for example, a straight or branched chain alkanoyl group having from 1 to 25 carbon atoms, such as the formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, lauroyl, tridecanoyl, myristoyl, palmitoyl, stearoyl, icosanoyl, docosanoyl and pentacosanoyl groups.
  • alkanoyl groups having from 1 to 12 carbon atoms we prefer those alkanoyl groups having from 1 to 12 carbon atoms, more preferably those alkanoyl groups having from 1 to 6 carbon atoms, still more preferably those alkanoyl groups having from 1 to 4 carbon atoms, and most preferably the acetyl and propionyl groups.
  • R 4 represents a cycloalkyl group
  • this is preferably a cycloalkyl group having from 3 to 8 carbon atoms, such as the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.
  • cycloalkyl group having from 3 to 7 carbon atoms more preferably those cycloalkyl groups having from 3 to 6 carbon atoms, and most preferably the cyclopropyl group.
  • R 4 represents an aryl group
  • this aryl group may be a carbocyclic aromatic hydrocarbon group having from 6 to 14 carbon atoms and may be unsubstituted or it may be substituted by at least one substituent selected from the group consisting of substituents a and substituents ⁇ .
  • the group may contain a single aromatic ring or it may contain two or more fused rings. Examples of such groups include the phenyl, indenyl, naphthyl, phenanthrenyl and anthracenyl groups. Of these, we prefer the phenyl and naphthyl groups, more preferably the phenyl group.
  • the above-mentioned aryl group may be condensed with a cycloalkyl group having from 3 to 10 carbon atoms and examples of such condensed groups include, for example, the 2-indanyl group.
  • R 4 represents an aralkyl group
  • this is an alkyl group, which may be any of the alkyl groups defined and exemplified above in relation to R etc., and which is substituted by from 1 to 3 aryl groups, as defined and exemplified above.
  • Such a group may be unsubstituted or it may be substituted by at least one of substituents a or ⁇ .
  • substituents a or ⁇ examples include the benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 1-naphthylmethyl, 2-naphthylmethyl, diphenylmethyl, triphenylmethyl, 1-naphthyldiphenylmethyl and 9-anthrylmethyl groups.
  • substituent ⁇ , substituent ⁇ 1 or substituent ⁇ 2 represents a lower alkoxy group
  • this may be, for example, a straight or branched chain alkoxy group having from 1 to 6 carbon atoms, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, t-butoxy, pentyloxy, isopentyloxy, 2-methylbutoxy, neopentyloxy, 1-ethylpropoxy, hexyloxy, isohexyloxy, 4-methylpentyloxy, 3-methylpentyloxy, 2-methylpentyloxy, 1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethylbutoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy or 2-ethylbutoxy groups.
  • straight or branched chain alkoxy groups having from 1 to 6
  • substituent ⁇ or substituent ⁇ 1 represents a lower alkylthio group
  • this may be a straight or branched chain alkylthio group having from 1 to 6 carbon atoms, and examples include the methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, t-butylthio, pentylthio, isopentylthio, 2-methylbutylthio, neopentylthio, 1-ethylpropylthio, hexylthio, isohexylthio, 4-methylpentylthio, 3-methylpentylthio, 2-methylpentylthio, 1-methylpentylthio, 3,3-dimethylbutylthio, 2,2-dimethylbutylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio,
  • substituent ⁇ represents a lower alkylsulfinyl group
  • this may be a straight or branched chain alkylsulfinyl group having from 1 to 6 carbon atoms, such as the methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl, t-butylsulfinyl, pentylsulfinyl, isopentylsulfinyl, 2-methylbutylsulfinyl, neopentylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl, isohexylsulfinyl, 4-methylpentylsulfinyl, 3-methylpentylsul
  • substituent ⁇ , substituent ⁇ 3 or substituent ⁇ 4 represents a cycloalkyloxy group
  • this may be, for example, a cycloalkyloxy group having from 3 to 8 carbon atoms, such as the cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy groups.
  • cycloalkyloxy groups having from 3 to 7 carbon atoms, more preferably the cycloalkyloxy groups having 5 or 6 carbon atoms, most preferably the cyclopentyloxy group.
  • substituent ⁇ , substituent ⁇ 1 or substituent ⁇ 2 represents a lower haloalkoxy group
  • this is an alkoxy group, which may be as defined and exemplified above in relation to substituent ⁇ etc., and which is substituted by at least one halogen atom, such as those defined and exemplified above.
  • Examples of such groups include the fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, chloromethoxy, trichloromethoxy, iodomethoxy and bromomethoxy groups.
  • lower haloalkoxy groups having from 1 to 4 carbon atoms, more preferably the fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 3-fluoropropoxy, 4-fluorobutoxy, chloromethoxy, trichloromethoxy and bromomethoxy groups, and most preferably the fluoromethoxy, difluoromethoxy and trifluoromethoxy groups.
  • substituent ⁇ , substituent ⁇ 1 or substituent ⁇ 2 represents a lower alkylenedioxy group
  • this may be, for example, a straight or branched chain alkylenedioxy group having from 1 to 6 carbon atoms, such as the methylenedioxy, ethylenedioxy, trimethylenedioxy, tetramethylenedioxy, pentamethylenedioxy, hexamethylenedioxy and propylenedioxy groups.
  • alkylenedioxy groups having from 1 to 4 carbon atoms, more preferably the methylenedioxy and ethylenedioxy groups.
  • substituent ⁇ 2 or substituent ⁇ 4 represents a lower alkyl group substituted with a halogen atom
  • this may be any of the alkyl groups defined and exemplified above in relation to R etc., which is substituted by at least one halogen atom, as also defined and exemplified above.
  • Examples of such groups include the fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl, 2-chloroethyl, 3-chloropropyl, bromomethyl, 2-bromoethyl, iodomethyl, 2-iodoethyl, chlorodifluoromethyl and bromodifluoromethyl groups.
  • haloalkyl groups having from 1 to 4 carbon atoms, more preferably the fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl and bromomethyl groups, and most preferably the fluoromethyl, difluoromethyl and trifluoromethyl groups.
  • R a represents a group to be eliminated in vivo is a group which can be eliminated in the human body under physiological conditions such as hydrolysis, that is a group producing a free amino group (—NH 2 ) from a group of formula —NHR a (wherein R a is as defined above). It is easy to determine whether or not the group can be eliminated in vivo by the following test: a compound to be tested is administered orally or intravenously to an experimental animal, such as a rat or mouse, and the body fluid is tested for the presence or absence of the corresponding compound having a free amino group or a pharmaceutically acceptable salt thereof.
  • Such groups include, for example:
  • alkanoyl groups having from 1 to 12 carbon atoms we prefer the alkanoyl groups having from 1 to 12 carbon atoms, the alkoxycarbonyl groups having from 2 to 5 carbon atoms, the aralkyloxycarbonyl groups having 7 to 8 carbon atoms, the alkanoyloxymethyl groups having from 3 to 6 carbon atoms, the alkoxycarbonyloxymethyl groups having from 3 to 6 carbon atoms and the 5-substituted (2-oxo-1,3-dioxolen-4-yl)methyl group, more preferably the acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, acetoxymethyl, propionyloxymethyl, methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl, (5-methyl-2-oxo-1,3-diox
  • R 1 preferably include the methyl, ethyl, amino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, valerylamino, isovalerylamino, pivaloylamino, methoxycarbonylamino, ethoxycarbonylamino, benzyloxycarbonylamino, acetoxymethylamino, propionyloxymethylamino, methoxycarbonyloxymethylamino, ethoxycarbonyloxymethylamino, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methylamino and (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methylamino groups, more preferably the methyl, amino and acetylamino groups, and most preferably the amino and acetylamino groups.
  • R 2 preferably include:
  • R 2 is a substituted phenyl group
  • the number of substituents is preferably from 1 to 3, more preferably 1 or 2.
  • R 3 preferably include hydrogen atoms; halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms; C 1 -C 4 alkyl groups, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups; and C 1 -C 4 haloalkyl groups, such as the fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, 4-fluorobutyl, 2-chloroethyl and 3-chloropropyl groups, more preferably hydrogen atoms; halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms; and the methyl, ethyl, fluoromethyl, difluoromethyl, 2-fluoroe
  • R 4 preferably include hydrogen atoms; C 1 -C 6 alkyl groups, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and hexyl groups; any of these alkyl groups having a substituent selected from hydroxy, halogen (such as fluorine, chlorine, bromine or iodine) and C 1 -C 4 alkoxy (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and t-butoxy); C 3 -C 7 cycloalkyl groups, such as the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl groups; C 6 -C 10 aryl groups, such as the phenyl and naphthyl groups, which may be unsubstid
  • R 4 include: hydrogen atoms; C 1 -C 4 alkyl groups, such as the methyl, ethyl, isopropyl, butyl and isobutyl groups; C 1 -C 4 mono-, di- or trihaloalkyl groups, such as the fluoromethyl, difluoromethyl, chlorodifluoromethyl, bromodifluoromethyl, trifluoromethyl, 2-fluoroethyl and 2,2,2-trifluoroethyl groups; hydroxymethyl groups; C 1 -C 4 alkoxymethyl groups, such as the methoxymethyl and ethoxymethyl groups; C 3 -C 6 cycloalkyl groups, such as the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups; phenyl groups; mono- or difluorophenyl groups, such as the 4-fluorophenyl and 2,4-difluorophenyl groups; mono-
  • Certain of the compounds of the present invention possess an acidic group and can thus form salts with cations.
  • the nature of the salt is not critical to the present invention, provided that it is pharmaceutically acceptable, that is that the salt is neither less active (or unacceptably less active) nor more toxic (or unacceptably more toxic) than the free acid.
  • Such salts include, for example: salts with alkali metals, such as sodium, potassium or lithium; salts with alkaline earth metals, such as calcium or magnesium; salts with other metals, such as aluminum, iron, zinc, copper, nickel or cobalt; other inorganic salts, such as the ammonium salt; salts with organic amines, such as t-octylamine, dibenzylamine, morpholine, glucosamine, phenylglycine alkyl ester, ethylenediamine, N-methylglucamine, guanidine, diethylamine, triethylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine, chloroprocaine, procaine, diethanolamine, N-benzyl-N-phenethylamine, piperazine, tetramethyl ammonium or tris(hydroxymethyl)aminomethane.
  • alkali metals such as sodium, potassium or lithium
  • the compounds of formula (I) and (II) and salts thereof sometimes absorb certain kinds of solvents to afford solvates, and such solvates are also included in the present invention.
  • Certain of the compounds of formula (I) and (II) of the present invention may have asymmetric carbon atoms in their molecule, and stereoisomers in the R-configuration or the S-configuration would then exist. Each of these stereoisomers and mixtures thereof in any desired proportion are all included in the present invention.
  • the compounds of the present invention have excellent activity for the prevention or inhibition of cachexia and very little toxicity, they are useful as preventive and therapeutic agents for cachexia. They are also useful for the treatment of tumor-related disorders, and can be used to inhibit the growth and/or metastasis of tumors.
  • one or more of the compounds of the present invention may be used in association with one or more other agents for the prevention or inhibition for tumor growth, and the compounds of the present invention and other agents may be administered simultaneously, separately or sequentially.
  • the other antitumor agent is preferably selected from a group consisting of 5-fluorouracil, cisplatin, tamoxifen, paclitaxel, docetaxel and irinotecan.
  • the compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof and the other antitumor agent may be contained in a single composition.
  • composition of the present invention may be in any conventional form, depending on the route of administration.
  • oral administration it may be in the form of tablets, capsules, granules, powders or syrups.
  • non-oral administration it may be in the form of injections or suppositories.
  • excipients e.g., organic excipients including sugar derivatives, such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives, such as corn starch, potato starch, ⁇ -starch and dextrin; cellulose derivatives, such as crystalline cellulose; gum arabic; dextran; and Pullulan, inorganic excipients including silicate derivatives, such as light silicic acid anhydride, synthetic aluminum silicate, calcium silicate and magnesium metasilicate aluminate; phosphates, such as calcium hydrogenphosphate; carbonates, such as calcium carbonate; and sulfates, such as calcium sulfate), lubricants (e.g., stearic acid and metal salts thereof, including stearic acid, calcium stearate and magnesium stearate; talc; colloidal silica; waxes,
  • excipients e.g., organic excipients including sugar derivatives, such as
  • the dose varies, depending on many factors, including the condition and age of the patients, the severity and nature of the disorder and the route of administration.
  • test animals were CDF1 mice (females, 8 weeks old). They were employed in groups of 10 for each test. 1 ⁇ 10 6 mouse colon cancer Colon 26 cells were transplanted subcutaneously into each animal.
  • test compounds were Compounds No. 1-94 and 2-78 as shown above in Tables 1 and 2, respectively, and having the following formulae:
  • test compound was suspended in sterlized distilled water containing 0.5% w/v carboxymethyl cellulose (CMC) and administered orally once per day starting on the day of the tumor cell transplantation.
  • CMC carboxymethyl cellulose
  • control group 1 was transplanted with the tumor cells but were not treated with any test compound, and the weight gain is reported as ⁇ g c1 ; the second control group (control group 2) were not transplanted with the tumor cells and were not treated with any test compound, and the weight gain is reported as ⁇ g c2 .
  • Body weight recovery rate was determined according to the following formula based on the weight gain on day 19 after tumor cell transplantation, and this value was used as an indicator of the anticachexia effect.
  • Body weight recovery rate (%) ( ⁇ g t ⁇ g c1 )/( ⁇ g c2 ⁇ g c1 ) ⁇ 100
  • Example 2 The procedure described in Example 1 was repeated, but using the compound of formula (III) as the test compound, and comparing the weight gain ( ⁇ g t ) of the test group of animals to which the compound of formula (III) had been administered with a control group ( ⁇ g c ) into which the tumor cells had been transplanted but to which no anti-tumor compound had been administered.
  • the test animals were female CDF1 mice, 16 weeks old. Also, the weight gain was measured 22 days after tumor transplantation. The average body weight of each group of animals immediately after tumor transplantation was 25 to 26 g. The results are shown in Table 4. TABLE 4 Dose Average Weight Compound (mg/kg) Gain ( ⁇ g) Compound (III) 10 0.9 Compound (III) 3 0.3 Compound (III) 1 0.0 None (Control group) — ⁇ 4.2
  • Example 2 The procedure described in Example 2 was repeated, but using the compound of formula (IV) as the test compound, and comparing the weight gain ( ⁇ g t ) of the test group of animals to which the compound of formula (IV) had been administered with a control group ( ⁇ g c ) into which the tumor cells had been transplanted but to which no anti-tumor compound had been administered.
  • the test animals were female CDF1 mice, 7 weeks old. Also, the weight gain was measured 15 days after tumor transplantation. The average body weight of each group of animals immediately after tumor transplantation was. 20 to 21 g. The results are shown in Table 5. TABLE 5 Dose Average Weight Compound (mg/kg) Gain ( ⁇ g) Compound (IV) 10 ⁇ 0.6 Compound (IV) 3 ⁇ 1.3 Compound (IV) 1 ⁇ 1.2 None (Control group) — ⁇ 3.4
  • Test compounds [the compounds of formula (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV)] are administered in the same manner as described in Example 2. These compounds inhibit mouse tumor cachexia and recover loss of average of body weight.
  • Example 1 Observation of the mice used in Example 1 above was continued. The life-prolonging index was determined, based on the number of days each mouse survived, and this value was then used as an indicator of the life-prolonging effects of the test compounds.
  • Life-prolonging index(%) ( S t /S c ⁇ 1) ⁇ 100
  • Example 5 The experiment reported in Example 5 was repeated with the animals used in Example 2. In the case of the group of mice treated with a test compound, oral administration of the respective compound once daily was continued on day 23 after tumor cell transplantation and beyond as well. The results are shown in Table 7. TABLE 7 Compound Dose Survival Period Life-prolonging Name (mg/kg) (median: days) Index (%) Compound (III) 10 43.5 91 Compound (III) 3 37.5 63 Compound (III) 1 40.5 76 None — 23.0 —
  • Example 5 The experiment reported in Example 5 is repeated with the animals used in Examples 3 and 4.
  • the compounds of formulae (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV) all inhibit mouse tumor cachexia and exhibit pronounced life-prolongation.
  • Mouse colon cancer cells are transplanted into CDF1 mice in the same manner as Example 1 followed by administration of the test compounds [Compound Nos. 2-78 and 1-94, and the compounds of formulae (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV)] and an antitumor agent (5-fluorouracil or cisplatin).
  • test compounds Compound Nos. 2-78 and 1-94, and the compounds of formulae (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV)] and an antitumor agent (5-fluorouracil or cisplatin).
  • mice each group containing ten C57BL/6 mice (female, age: 8 weeks) were transplanted intravenously into the tail vein with 3 ⁇ 10 4 of mouse malignant melanoma B16-BL6 cells.
  • mice were, when necessary, administered intravenously into the tail vein with a bacterial lipopolysaccharide (LPS) in an amount of 3 ⁇ g each within one hour before transplantation of the melanoma cells so as to accelerate lung metastasis of the melanoma [M. J. Anasagasti et al., J. Natl. Cancer Research, 89, 645-651 (1997).]
  • LPS bacterial lipopolysaccharide
  • Compound No. 2-118 a compound of formula (IV), a compound of formula (V) and indomethacin were employed, and each was suspended in sterilized distilled water containing 0.5% w/v of carboxymethyl cellulose (CMC), and the suspensions were orally administered at a dose of 1 mg/kg per day for five days starting from the day of the melanoma cell transplantation.
  • CMC carboxymethyl cellulose
  • Compound No. 2-118 is 2-(3,4-dimethylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole.
  • LMI lung metastasis inhibitory rate
  • the present composition showed a marked inhibition of lung metastasis, while the compound of formula (IV) and the compound of formula (V), which are COX-2-selective inhibitors, and indomethacin, which is a typical NSAID, had no such inhibitory activity under the lung metastasis accelerating conditions caused by inducing inflammatory reaction (as reflecting acceleration of metastasis of tumor in a surgical operation of resecting a tumor).
  • mice 1 ⁇ 10 6 mouse sarcoma S-180 cells were transplanted subcutaneously in Balb/c nude mice (females, 8 weeks old) in groups of 10 each.
  • test compound Compound No. 2-118
  • CMC carboxymethyl cellulose
  • GI (%) (1 ⁇ V t /V c ) ⁇ 100
  • Human colon cancer KM12-HX cells were orthotopically transplanted into the cecum of nude mice according to the method of Fu et al. [X. Fu et al., Anticancer Res., 12 (1992)] using Balb/c nude mice (females, 7 weeks old) in groups of 10 each.
  • an incision was made into the left lower abdominal region of each mouse under Abacin anesthesia, after which a thin section of tumor measuring 5 mm on a side was sutured to the cecum using absorbable surgical sutures to perform orthotopic transplant.
  • the incision was sutured using absorbable surgical sutures and the mice were warmed and promptly awakened from anesthesia.
  • test compound was suspended in sterilized distilled water containing 0.5% w/v carboxymethyl cellulose (CMC) and administered orally in a total of 9 doses consisting of one dose per day from days 3 to 7 after the tumor cell transplantation and from days 10 to 13 after the transplantation.
  • CMC carboxymethyl cellulose
  • GI (%) (1 ⁇ V t ′/V c ′) ⁇ 100
  • composition of the present invention inhibited the growth of human colon cancer cells at the orthotopic transplantation site.
  • a mixture of a compound of the present invention such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, is prepared in a digestive oily substance, such as soybean oil, cottonseed oil or olive oil, and filled into gelatin with a positive replacement pump to obtain soft capsules containing 100 mg of active ingredient. The resulting capsules are then washed and dried.
  • a digestive oily substance such as soybean oil, cottonseed oil or olive oil
  • Tablets are manufactured in accordance with conventional methods using 100 mg of a compound of the present invention, such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose.
  • a compound of the present invention such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose.
  • the tablets can be coated with a preparation coating if desired.
  • a compound of the present invention such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, is stirred in 10% by volume of propylene glycol, and is then adjusted to a constant volume by the addition of water for injection, after which it was sterilized to prepare injections.
  • a suspension is produced so as to contain 100 mg of a compound of the present invention, such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, which is ground into a fine powder, 100 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution (Japanese Pharmacopoeia) and 0.025 ml of vanillin in 5 ml of the suspension.
  • a compound of the present invention such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, which is ground into a fine powder, 100 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution (Japanese Pharmacopoeia) and 0.025 ml of vanillin in 5 ml of the suspension.

Abstract

Certain cyclooxygenase-2 inhibitors are useful for the treatment and prevention of tumors and tumor-related disorders and cachexia.

Description

    BACKGROUND TO THE INVENTION
  • The present invention relates to the use of certain compounds, specifically cyclooxygenase-2 inhibitors (hereinafter referred to as “COX-2 inhibitors”) for the treatment and prevention of tumors and tumor-related disorders and cachexia.
  • Cachexia is a systemic disease of which the cardinal symptoms are progressive weight loss, anemia, edema, loss of appetite and so forth. It may occur as a side-effect of certain chronic diseases, such as malignant tumors, tuberculosis, diabetes, blood diseases, endocrine diseases, infections and acquired immune deficiency syndrome. When cachexia occurs as a result of the presence of a malignant tumor, even if the administration of antitumor drugs to the patient with malignant tumor is effective and antitumor effects are experienced, there is normally no improvement in the cachexia because of adverse effects such as the myelotoxicity which may be caused by the antitumor drug.
  • The treatment of cachexia is often very difficult for the following reasons:
  • Since the strength of a patient is greatly depleted as cachexia progresses, it may become impossible to continue treatment using antitumor drugs (which generally exhibit a high level of toxicity), and this thereby becomes an obstacle to the treatment of the malignant tumor.
  • Nutritional supplements are often given in order to treat the symptoms of cachexia. This, however, often enhances the progress of the malignant tumor, and may shorten the survival time of the patient.
  • At present, no satisfactory treatment for cachexia has been established, and there is an increasing need for agents that alleviate the symptoms of cachexia.
  • The compounds of formula (I) or (II), shown below, which, with certain other compounds, are the active ingredients of the compositions of the present invention, are known to inhibit selectively cyclooxygenase-2 (COX-2). They are also known to inhibit the production of inflammatory cytokines (particularly IL-1 and TNF-α), to inhibit the production of leukotrienes particularly LTB4), to inhibit bone resorption, and to have analgesic, anti-inflammatory and anti-pyretic effects (European Patent Publication No. 799 823A).
    Figure US20050004109A1-20050106-C00001
  • It has not previously been known that these compounds can be used for the treatment or prevention of cachexia.
  • Also, although it is known that certain other active ingredients employed in the present invention, namely the compounds of formula (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV) have selective inhibitory activity against cyclooxygenase-2, an inhibitory effect on the production of inflammatory cytokines (particularly IL-1 and TNF-α), an inhibitory action on the production of leukotrienes (particularly LTB4), an inhibitory action on bone resorption, an analgesic action, an anti-inflammatory action and an antipyretic action [International publication number WO95/00501, J. Med. Chem., 40, 1347 (1997), International publication number WO94/13635, Pharmacology, 55, 44 (1997), Prostaglandins, 47, 55 (1994), Japanese publication number Hei 9-52882, Jpn. J. Pharmacol., 67,305 (1995), Inflamm. Res., 47, Suppl. 3, S257 (1997), J. Med. Chem., 38, 4570 (1995), U.S. Pat. No. 5,474,995, European Patent No. 863 134 and International Patent Publication No. WO 98/06708], it has not previously been disclosed that these compounds have an effect against cachexia.
  • It is known from epidemiological studies that the taking of conventional NSAIDS (non-steroidal anti-inflammatory drugs, which are COX-1 and COX-2 inhibitors), the most common of which is aspirin, and the incidence of colon cancer have an inverse correlation. In addition, there have been many reports that NSAIDS, such as aspirin and sulindac, have shown inhibitory activity against tumor metastasis and carcinogenesis in preclinical studies. Some NSAIDS have been used in clinical studies for the prevention of colon carcinogenesis.
  • However, since conventional NSAIDS are not selective for COX-1 or COX-2, the occurrence of adverse effects is unavoidable.
  • It would, therefore, be desirable to discover a selective cyclooxygenase-2 inhibitor (selective COX-2 inhibitor) for use as an anti-tumor agent that has a low level of adverse effects.
  • Among the known selective COX-2 inhibitors, it is known that MF-tricyclic [Oshima, M. et al. “Suppression of Intestinal Polyposis in APCΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)”, Cell, 87, 803-809 (1996)] and celecoxib (Reddy, R. S. et al. “Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis”, Cancer Res., 56, 4566-4569 (1996)] inhibit the occurrence of experimental colonic polyposis, and that SC-58125 exhibits growth inhibitory effects against certain types of human colon cancer cell lines (Sheng, H. et al. “Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2”, J. Clin. Invest., 99, 2254-2259 (1997)].
  • However, in the case of the former, the experimental system used is not a model for an established colon cancer, and the compounds are only able to prevent the occurrence of polyposis in the preliminary stage of colon cancer.
  • On the other hand, with respect to the latter, the only colon cancer cell line in which growth inhibitory effects against human colon cancer cell lines have been observed is a cell line that expresses cyclooxygenase-2 (human colon cancer cell line HCA-7), and it has been disclosed that colon cancer cell lines that do not exhibit tumor growth inhibitory activity (HCT-116) in vitro do not exhibit tumor growth inhibitory effects in vivo. Thus, whether or not COX-2 inhibitor-induced tumor growth inhibitory effects on colon cancer are expressed in vivo depends on the sensitivity of the colon cancer cell lines used against COX-2 inhibitor-induced cell growth inhibitory activity in vitro. It is thus unlikely that the tumor growth inhibitory effects of COX-2 inhibitors in vivo would be observed against various other cancers, especially those cancers, including colon cancers, that are resistant to COX-2 inhibitor-induced inhibition of cell growth in vitro and that do not express cyclooxygenase-2.
  • Moreover, there has been no previous disclosure of the use of a combination of a selective cyclooxygenase-2 inhibitor and a 5-fluorouracil derivative for the prevention or inhibition of tumor growth.
  • We have now found that certain 1,2-diphenylpyrrole derivatives and closely related compounds have excellent activity for the prevention or inhibition of cachexia, and that these 1,2-diphenylpyrrole derivatives are effective for the treatment or prevention of tumor-related disorders, alone or in combination with a 5-fluorouracil derivative.
    • BRIEF SUMMARY OF THE INVENTION
  • Thus, in a first embodiment, the present invention provides a method for the treatment or prevention of cachexia in a mammal, which may be human, in need of such treatment or prevention, which method comprises administering to said mammal an effective amount of an active compound selected from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV):
    Figure US20050004109A1-20050106-C00002
    Figure US20050004109A1-20050106-C00003
    Figure US20050004109A1-20050106-C00004
    wherein
      • R represents a hydrogen atom, a halogen atom or a lower alkyl group;
      • R1 represents a lower alkyl group, an amino group or a group of formula —NHRa (wherein Ra represents a group which may be eliminated in vivo);
      • R2 represents a phenyl group or a phenyl group having at least one substituent selected from the group consisting of substituents α and substituents β, defined below;
      • R3 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkyl group having at least one substituent selected from the group consisting of substituents α;
      • R4 represents a hydrogen atom, a lower alkyl group, a lower alkyl group having at least one substituent selected from the group consisting of substituents α, a cycloalkyl group, an aryl group as defined below, or an aralkyl group as defined below;
      • said aryl group is a carbocyclic aromatic hydrocarbon group having from 6 to 14 carbon atoms in one or more aromatic rings or such a group which is fused to a cycloalkyl group having from 3 to 10 carbon atoms, and the group is unsubstituted or it is substituted by at least one substituent selected from the group consisting of substituents α and substituents β;
      • said aralkyl group is a lower alkyl group which is substituted by one or more of the aryl groups defined above;
      • tBu represents a t-butyl group;
      • Et represents an ethyl group; and
      • Ph represents a phenyl group;
      • said substituents α are selected from the group consisting of hydroxy groups, halogen atoms, lower alkoxy groups and lower alkylthio groups; and
      • said substituents β are selected from the group consisting of lower alkyl groups, alkanoyloxy groups, mercapto groups, alkanoylthio groups, lower alkylsulfinyl groups, lower alkyl groups having at least one substituent selected from the group consisting of substituents α, cycloalkyloxy groups, lower haloalkoxy groups and lower alkylenedioxy groups;
        and pharmaceutically acceptable salts thereof.
  • The invention further provides a method for the treatment or prevention of tumor-related disorders in a mammal, which may be human, in need of such treatment or prevention, which method comprises administering to said mammal an effective amount of an active compound selected from the group consisting of compounds of formula (I) and (II), defined above.
    • DETAILED DESCRIPTION OF INVENTION
  • Preferred classes of compounds of the present invention are those compounds of formula (I) and (II) in which:
    • (1) R represents a hydrogen atom, a fluorine atom, a chlorine atom or a methyl group, more preferably the hydrogen atom,
    • (2) R1 represents a methyl group, an amino group or an acetylamino group, more preferably the amino group or acetylamino group,
    • (3) R2 represents a phenyl group or a phenyl group having at least one substituent selected from the group consisting of substituents α1 and substituents β1, more preferably a phenyl group or phenyl group having at least one substituent selected from the group consisting of substituents α1 and substituents β2, still more preferably a phenyl group in which the number of substituents is from 1 to 3,
    • (4) R3 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkyl group having at least one substituent selected from the group consisting of substituents α1, more preferably a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkyl group substituted with a halogen atom,
    • (5) R4 represents a hydrogen atom, a lower alkyl group, a lower alkyl group having at least one substituent selected from the group consisting of substituents α, a cycloalkyl group, an aryl group, an aryl group having at least one substituent selected from the group consisting of substituents α1 and substituents β3 an aralkyl group or an aralkyl group having at least one substituent selected from the group consisting of substituents α1 and substituents β3, more preferably a hydrogen atom, a lower alkyl group, a lower alkyl group having at least one substituent selected from the group consisting of substituents α2, a cycloalkyl group, an aryl group, an aryl group having at least one substituent selected from the group consisting of substituents α2 and substituents β4, an aralkyl group or an aralkyl group having at least one substituent selected from the group consisting of substituents α2 and substituents β4.
  • Said substituents α1 are selected from the group consisting of halogen atoms, lower alkoxy groups and lower alkylthio groups.
  • Said substituents α2 are selected from the group consisting of hydroxy groups, halogen atoms and lower alkoxy groups.
  • Said substituents β1 are selected from the group consisting of lower alkyl groups, mercapto groups, alkanoylthio groups, lower alkyl groups having at least one substituent selected from the group consisting of substituents α1, lower haloalkoxy groups and lower alkylenedioxy groups.
  • Said substituents β2 are selected from the group consisting of lower alkyl groups, mercapto groups, alkanoylthio groups, lower alkyl groups substituted with a halogen atom, lower haloalkoxy groups and lower alkylenedioxy groups.
  • Said substituents β3 are selected from the group consisting of lower alkyl groups, lower alkyl groups having at least one substituent selected from the group consisting of substituents a and cycloalkyloxy groups.
  • Said substituents β4 are selected from the group consisting of lower alkyl groups, lower alkyl groups substituted with a halogen atom and cycloalkyloxy groups.
  • In the compounds of formula (I) and (II), where R, R3, substituents a, substituents α1 or substituents α2 represents a halogen atom, or where substituents β2 or substituents β4 represents a lower alkyl group substituted with halogen atom, the halogen atom is preferably a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom, a chlorine atom or a bromine atom.
  • Where R, R1, R3, R4, substituent β, substituent β1, substituent β2, substituent β3 or substituent β4 represents a lower alkyl group, or R3, R4, substituent β, substituent β1 or substituent β3 represents a lower alkyl group having at least one substituent selected from the group consisting of substituents α, or substituent β2 or substituent β4 represents a lower alkyl group substituted with a halogen atom, the alkyl group or alkyl part of the substituted group may be a straight or branched chain alkyl group having from 1 to 6 carbon atoms, and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl and 2-ethylbutyl groups. Of these, we prefer the straight or branched chain alkyl groups having from 1 to 4 carbon atoms, more preferably the methyl and ethyl groups. In R, R1 and R4, the lower alkyl group is particularly preferably the methyl group.
  • Where substituent β represents an alkanoyloxy group, or substituent β, substituent β1 or substituent β2 represents an alkanoylthio group, the alkanoyl part of these groups may be, for example, a straight or branched chain alkanoyl group having from 1 to 25 carbon atoms, such as the formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, lauroyl, tridecanoyl, myristoyl, palmitoyl, stearoyl, icosanoyl, docosanoyl and pentacosanoyl groups. Of these, we prefer those alkanoyl groups having from 1 to 12 carbon atoms, more preferably those alkanoyl groups having from 1 to 6 carbon atoms, still more preferably those alkanoyl groups having from 1 to 4 carbon atoms, and most preferably the acetyl and propionyl groups.
  • Where R4 represents a cycloalkyl group, this is preferably a cycloalkyl group having from 3 to 8 carbon atoms, such as the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups. Of these, we prefer those cycloalkyl group having from 3 to 7 carbon atoms, more preferably those cycloalkyl groups having from 3 to 6 carbon atoms, and most preferably the cyclopropyl group.
  • Where R4 represents an aryl group, this aryl group may be a carbocyclic aromatic hydrocarbon group having from 6 to 14 carbon atoms and may be unsubstituted or it may be substituted by at least one substituent selected from the group consisting of substituents a and substituents β. The group may contain a single aromatic ring or it may contain two or more fused rings. Examples of such groups include the phenyl, indenyl, naphthyl, phenanthrenyl and anthracenyl groups. Of these, we prefer the phenyl and naphthyl groups, more preferably the phenyl group. The above-mentioned aryl group may be condensed with a cycloalkyl group having from 3 to 10 carbon atoms and examples of such condensed groups include, for example, the 2-indanyl group.
  • Where R4 represents an aralkyl group, this is an alkyl group, which may be any of the alkyl groups defined and exemplified above in relation to R etc., and which is substituted by from 1 to 3 aryl groups, as defined and exemplified above. Such a group may be unsubstituted or it may be substituted by at least one of substituents a or β. Examples of such groups include the benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 1-naphthylmethyl, 2-naphthylmethyl, diphenylmethyl, triphenylmethyl, 1-naphthyldiphenylmethyl and 9-anthrylmethyl groups. Of these, we prefer an alkyl group having from 1 to 4 carbon atoms which is substituted with one aryl group having from 6 to 10 carbon atoms.
  • Where substituent α, substituent α1 or substituent α2 represents a lower alkoxy group, this may be, for example, a straight or branched chain alkoxy group having from 1 to 6 carbon atoms, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, t-butoxy, pentyloxy, isopentyloxy, 2-methylbutoxy, neopentyloxy, 1-ethylpropoxy, hexyloxy, isohexyloxy, 4-methylpentyloxy, 3-methylpentyloxy, 2-methylpentyloxy, 1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethylbutoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy or 2-ethylbutoxy groups. Of these, we prefer the straight or branched chain alkoxy groups having from 1 to 4 carbon atoms, more preferably the methoxy and ethoxy groups.
  • Where substituent α or substituent α1 represents a lower alkylthio group, this may be a straight or branched chain alkylthio group having from 1 to 6 carbon atoms, and examples include the methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, t-butylthio, pentylthio, isopentylthio, 2-methylbutylthio, neopentylthio, 1-ethylpropylthio, hexylthio, isohexylthio, 4-methylpentylthio, 3-methylpentylthio, 2-methylpentylthio, 1-methylpentylthio, 3,3-dimethylbutylthio, 2,2-dimethylbutylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,3-dimethylbutylthio and 2-ethylbutylthio groups. Of these, we prefer the straight or branched chain alkylthio groups having from 1 to 4 carbon atoms, more preferably the methylthio and ethylthio groups.
  • Where substituent β represents a lower alkylsulfinyl group, this may be a straight or branched chain alkylsulfinyl group having from 1 to 6 carbon atoms, such as the methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl, t-butylsulfinyl, pentylsulfinyl, isopentylsulfinyl, 2-methylbutylsulfinyl, neopentylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl, isohexylsulfinyl, 4-methylpentylsulfinyl, 3-methylpentylsulfinyl, 2-methylpentylsulfinyl, 1-methylpentylsulfinyl, 3,3-dimethylbutylsulfinyl, 2,2-dimethylbutylsulfinyl, 1,1-dimethylbutylsulfinyl, 1,2-dimethylbutylsulfinyl, 1,3-dimethylbutylsulfinyl, 2,3-dimethylbutylsulfinyl and 2-ethylbutylsulfinyl groups. Of these, we prefer the straight or branched chain alkylsulfinyl groups having from 1 to 4 carbon atoms.
  • Where substituent β, substituent β3 or substituent β4 represents a cycloalkyloxy group, this may be, for example, a cycloalkyloxy group having from 3 to 8 carbon atoms, such as the cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy groups. Of these, we prefer the cycloalkyloxy groups having from 3 to 7 carbon atoms, more preferably the cycloalkyloxy groups having 5 or 6 carbon atoms, most preferably the cyclopentyloxy group.
  • Where substituent β, substituent β1 or substituent β2 represents a lower haloalkoxy group, this is an alkoxy group, which may be as defined and exemplified above in relation to substituent α etc., and which is substituted by at least one halogen atom, such as those defined and exemplified above. Examples of such groups include the fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, chloromethoxy, trichloromethoxy, iodomethoxy and bromomethoxy groups. Of these, we prefer those lower haloalkoxy groups having from 1 to 4 carbon atoms, more preferably the fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 3-fluoropropoxy, 4-fluorobutoxy, chloromethoxy, trichloromethoxy and bromomethoxy groups, and most preferably the fluoromethoxy, difluoromethoxy and trifluoromethoxy groups.
  • Where substituent β, substituent β1 or substituent β2 represents a lower alkylenedioxy group, this may be, for example, a straight or branched chain alkylenedioxy group having from 1 to 6 carbon atoms, such as the methylenedioxy, ethylenedioxy, trimethylenedioxy, tetramethylenedioxy, pentamethylenedioxy, hexamethylenedioxy and propylenedioxy groups. Of these, we prefer those alkylenedioxy groups having from 1 to 4 carbon atoms, more preferably the methylenedioxy and ethylenedioxy groups.
  • Where substituent β2 or substituent β4 represents a lower alkyl group substituted with a halogen atom, this may be any of the alkyl groups defined and exemplified above in relation to R etc., which is substituted by at least one halogen atom, as also defined and exemplified above. Examples of such groups include the fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl, 2-chloroethyl, 3-chloropropyl, bromomethyl, 2-bromoethyl, iodomethyl, 2-iodoethyl, chlorodifluoromethyl and bromodifluoromethyl groups. Of these, we prefer those haloalkyl groups having from 1 to 4 carbon atoms, more preferably the fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl and bromomethyl groups, and most preferably the fluoromethyl, difluoromethyl and trifluoromethyl groups.
  • Where Ra represents a group to be eliminated in vivo is a group which can be eliminated in the human body under physiological conditions such as hydrolysis, that is a group producing a free amino group (—NH2) from a group of formula —NHRa (wherein Ra is as defined above). It is easy to determine whether or not the group can be eliminated in vivo by the following test: a compound to be tested is administered orally or intravenously to an experimental animal, such as a rat or mouse, and the body fluid is tested for the presence or absence of the corresponding compound having a free amino group or a pharmaceutically acceptable salt thereof. Such groups include, for example:
      • the alkanoyl groups defined and exemplified above in relation to substituent β etc.;
      • a lower alkoxycarbonyl group, in which the alkoxy group is as defined and exemplified above in relation to substituent a etc., such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and cyclohexyloxycarbonyl groups;
      • an aralkyloxycarbonyl group in which the aryl is as defined above and is unsubstituted or is substituted by one or two lower alkoxy or nitro groups, such as the benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl groups;
      • an alkanoyloxymethyl group in which the alkanoyl group is as defined and exemplified above in relation to substituent P etc., such as the formyloxy-methyl, acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl, valeryloxymethyl, isovaleryloxymethyl and hexanoyloxymethyl groups;
      • a lower alkoxycarbonyloxymethyl group in which the alkoxy group is as defined and exemplified above in relation to substituent α etc., such as the methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl, propoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl, butoxycarbonyloxymethyl, isobutoxycarbonyloxymethyl and pentyloxycarbonyloxymethyl groups; and
      • a (2-oxo-1,3-dioxolen-4-yl)methyl group in which the 5-position of the dioxolene ring may be substituted with a lower alkyl group or an aryl group, as defined and exemplified above in relation to R and R4, respectively, such as the (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl, [5-(4-methylphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, [5-(4-methoxyphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, [5-(4-fluorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, [5-(4-chlorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, (2-oxo-1,3-dioxolen-4-yl)methyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-ethyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-propyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-isopropyl-2-oxo-1,3-dioxolen-4-yl)methyl and (5-butyl-2-oxo-1,3-dioxolen-4-yl)methyl groups.
  • Of these, we prefer the alkanoyl groups having from 1 to 12 carbon atoms, the alkoxycarbonyl groups having from 2 to 5 carbon atoms, the aralkyloxycarbonyl groups having 7 to 8 carbon atoms, the alkanoyloxymethyl groups having from 3 to 6 carbon atoms, the alkoxycarbonyloxymethyl groups having from 3 to 6 carbon atoms and the 5-substituted (2-oxo-1,3-dioxolen-4-yl)methyl group, more preferably the acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, acetoxymethyl, propionyloxymethyl, methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl and (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl groups, and most preferably the acetyl group.
  • Specific examples of R1 preferably include the methyl, ethyl, amino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, valerylamino, isovalerylamino, pivaloylamino, methoxycarbonylamino, ethoxycarbonylamino, benzyloxycarbonylamino, acetoxymethylamino, propionyloxymethylamino, methoxycarbonyloxymethylamino, ethoxycarbonyloxymethylamino, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methylamino and (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methylamino groups, more preferably the methyl, amino and acetylamino groups, and most preferably the amino and acetylamino groups.
  • Specific examples of R2 preferably include:
      • the unsubstituted phenyl group;
      • phenyl groups having from 1 to 3 substituents selected from mercapto groups, C1-C4 alkanoylthio groups, halogen atoms, C1-C4 alkyl groups, C1-C4 alkoxy groups, C1-C4 alkylthio groups and C1-C4 alkylsulfinyl groups, such as the 4-mercaptophenyl, 4-acetylthiophenyl, 4-propionylthiophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, p-tolyl, 4-ethylphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-methylthiophenyl, 4-ethylthiophenyl, 4-methylsulfinylphenyl, 4-ethylsulfinylphenyl, 3,4-difluorophenyl, 2,4-difluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dimethylphenyl, 3,4-dimethoxyphenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-methyl-4-methoxyphenyl, 3,5-dichloro-4-methoxyphenyl and 4-methoxy-3,5-dimethylphenyl groups;
      • trifluoromethyl-, difluoromethoxy- or trifluoromethoxy-substituted phenyl groups, such as the 4-trifluoromethylphenyl, 4-difluoromethoxyphenyl and 4-trifluoromethoxyphenyl groups;
      • methylenedioxy- or ethylenedioxy-substituted phenyl group such as the 3,4-methylenedioxyphenyl and 3,4-ethylenedioxyphenyl groups.
  • In the case where R2 is a substituted phenyl group, the number of substituents is preferably from 1 to 3, more preferably 1 or 2.
  • Specific examples of R3 preferably include hydrogen atoms; halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms; C1-C4 alkyl groups, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups; and C1-C4 haloalkyl groups, such as the fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, 4-fluorobutyl, 2-chloroethyl and 3-chloropropyl groups, more preferably hydrogen atoms; halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms; and the methyl, ethyl, fluoromethyl, difluoromethyl, 2-fluoroethyl and 2-chloroethyl groups.
  • Specific examples of R4 preferably include hydrogen atoms; C1-C6 alkyl groups, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and hexyl groups; any of these alkyl groups having a substituent selected from hydroxy, halogen (such as fluorine, chlorine, bromine or iodine) and C1-C4 alkoxy (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and t-butoxy); C3-C7 cycloalkyl groups, such as the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl groups; C6-C10 aryl groups, such as the phenyl and naphthyl groups, which may be unsubstituted or may have one or more of the following substituents y; C6-C10 aryl C1-C4 alkyl groups, such as the benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 1-naphthylmethyl and 2-naphthylmethyl groups, which may be unsubstituted or may have one or more of the following substituents y in the aryl moiety;
      • substituents γ include: halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms; C1-C4 alkyl groups, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups; C1-C4 haloalkyl groups, such as the fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, trichloromethyl, chlorodifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 3-fluoropropyl and 4-fluoropropyl groups; C1-C4 alkoxy groups, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and t-butoxy groups; and C3-C7 cycloalkyloxy groups, such as the cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy groups.
  • Preferred examples of R4 include: hydrogen atoms; C1-C4 alkyl groups, such as the methyl, ethyl, isopropyl, butyl and isobutyl groups; C1-C4 mono-, di- or trihaloalkyl groups, such as the fluoromethyl, difluoromethyl, chlorodifluoromethyl, bromodifluoromethyl, trifluoromethyl, 2-fluoroethyl and 2,2,2-trifluoroethyl groups; hydroxymethyl groups; C1-C4 alkoxymethyl groups, such as the methoxymethyl and ethoxymethyl groups; C3-C6 cycloalkyl groups, such as the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups; phenyl groups; mono- or difluorophenyl groups, such as the 4-fluorophenyl and 2,4-difluorophenyl groups; mono- or dimethoxyphenyl groups, such as the 4-methoxyphenyl and 3,4-dimethoxyphenyl groups; tolyl groups, such as the p-tolyl and o-tolyl groups; cyclopentyloxy-(methoxy)phenyl groups, such as the 3-cyclopentyloxy-4-methoxyphenyl group; trifluoromethylphenyl groups, such as the 4-trifluoromethylphenyl group; benzyl groups; substituted benzyl groups, such as the 4-methoxybenzyl and 3-cyclopentyl-oxy-4-methoxybenzyl groups; phenethyl groups; naphthyl groups, such as the 1-naphthyl and 2-naphthyl groups; and naphthylmethyl groups, such as the 1-naphthylmethyl and 2-naphthylmethyl groups.
  • Certain of the compounds of the present invention, specifically the compounds of formula (I) and (II), possess an acidic group and can thus form salts with cations. The nature of the salt is not critical to the present invention, provided that it is pharmaceutically acceptable, that is that the salt is neither less active (or unacceptably less active) nor more toxic (or unacceptably more toxic) than the free acid. Such salts include, for example: salts with alkali metals, such as sodium, potassium or lithium; salts with alkaline earth metals, such as calcium or magnesium; salts with other metals, such as aluminum, iron, zinc, copper, nickel or cobalt; other inorganic salts, such as the ammonium salt; salts with organic amines, such as t-octylamine, dibenzylamine, morpholine, glucosamine, phenylglycine alkyl ester, ethylenediamine, N-methylglucamine, guanidine, diethylamine, triethylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine, chloroprocaine, procaine, diethanolamine, N-benzyl-N-phenethylamine, piperazine, tetramethyl ammonium or tris(hydroxymethyl)aminomethane.
  • Further, when the compounds of formula (I) and (II) and salts thereof are allowed to stand in the atmosphere, they may adsorb moisture to form hydrates. Such hydrates are also included in the present invention.
  • Further, the compounds of formula (I) and (II) and salts thereof sometimes absorb certain kinds of solvents to afford solvates, and such solvates are also included in the present invention.
  • Certain of the compounds of formula (I) and (II) of the present invention may have asymmetric carbon atoms in their molecule, and stereoisomers in the R-configuration or the S-configuration would then exist. Each of these stereoisomers and mixtures thereof in any desired proportion are all included in the present invention.
  • Specific examples of the compounds of formula (I) and (II) employed in the method and composition of the present invention include, for example, those shown in the following Table 1 [compounds of formula (I)] and Table 2 [compounds of formula (II)].
  • In the Tables, the following abbreviations are used:
      • Ac acetyl;
      • Bu butyl;
      • Byr butyryl;
      • iByr isobutyryl;
      • Bz benzyl;
      • Et ethyl;
      • For formyl;
      • Me methyl;
      • Ph phenyl;
      • Piv pivaloyl;
      • cPn cyclopentyl;
      • Pr propyl;
      • cPr cyclopropyl;
      • iPr isopropyl;
      • PM propionyl;
      • iVal isovaleryl; and
  • Val valeryl.
    TABLE 1
    Cpd. No. R R1 R2 R3 R4
    1-1 H Me Ph H H
    1-2 H Me Ph H Me
    1-3 H Me 4-F—Ph H H
    1-4 H Me 4-F—Ph F H
    1-5 H Me 4-F—Ph Cl H
    1-6 H Me 4-F—Ph Br H
    1-7 H Me 4-F—Ph I H
    1-8 H Me 4-F—Ph Me H
    1-9 H Me 4-F—Ph Et H
    1-10 H Me 4-F—Ph Pr H
    1-11 H Me 4-F—Ph Bu H
    1-12 H Me 4-F—Ph CH2F H
    1-13 H Me 4-F—Ph CHF2 H
    1-14 H Me 4-F—Ph CF3 H
    1-15 H Me 4-F—Ph H Me
    1-16 H Me 4-F—Ph F Me
    1-17 H Me 4-F—Ph Cl Me
    1-18 H Me 4-F—Ph Br Me
    1-19 H Me 4-F—Ph I Me
    1-20 H Me 4-F—Ph Me Me
    1-21 H Me 4-F—Ph Et Me
    1-22 H Me 4-F—Ph Pr Me
    1-23 H Me 4-F—Ph H Et
    1-24 H Me 4-F—Ph H Pr
    1-25 H Me 4-F—Ph H Bu
    1-26 H Me 4-F—Ph H cPr
    1-27 H Me 4-F—Ph H Ph
    1-28 H Me 4-F—Ph H CH2Ph
    1-29 H Me 4-F—Ph H CHF2
    1-30 H Me 4-F—Ph Me CHF2
    1-31 H Me 4-F—Ph H CF3
    1-32 H Me 4-F—Ph Me CF3
    1-33 H Me 4-MeO—Ph H H
    1-34 H Me 4-MeO—Ph H Me
    1-35 H Me 4-Cl—Ph H H
    1-36 H Me 4-Cl—Ph H Me
    1-37 H Me 4-Me—Ph H H
    1-38 H Me 4-Me—Ph H Me
    1-39 H Me 3-Cl-4-F—Ph H H
    1-40 H Me 3-Cl-4-F—Ph H Me
    1-41 H Me 3,4-methylenedioxy-Ph H H
    1-42 H Me 3,4-methylenedioxy-Ph H Me
    1-43 H Me 3-Cl-4-MeO—Ph H H
    1-44 H Me 3-Cl-4-MeO—Ph H Me
    1-45 H Me 4-CF3—Ph H H
    1-46 H Me 4-CF3O—Ph H H
    1-47 H Me 3-F-4-MeO—Ph H H
    1-48 H Me 3-F-4-MeO—Ph H Me
    1-49 H Me 3-Me-4-MeO—Ph H H
    1-50 H Me 3-Me-4-MeO—Ph H Me
    1-51 H Me 3,4-diF—Ph H H
    1-52 H Me 3,4-diF—Ph H Me
    1-53 H Me 2,4-diF—Ph H H
    1-54 H Me 2,4-diF—Ph H Me
    1-55 H Me 3,4-diMe—Ph H H
    1-56 H Me 3,4-diMe—Ph H Me
    1-57 H Me 3,4-diCl—Ph H H
    1-58 H Me 3,4-diCl—Ph H Me
    1-59 H Me 3,4-di(MeO)—Ph H H
    1-60 H Me 3,4-di(MeO)—Ph H Me
    1-61 H Me 4-F—Ph H CH2OH
    1-62 H Me 4-F—Ph Me CH2OH
    1-63 H Me 4-F—Ph H CH2OMe
    1-64 H Me 4-MeO—Ph H CH2OH
    1-65 H Me 4-MeO—Ph H CH2OMe
    1-66 H Me 4-Cl—Ph H CH2OH
    1-67 H Me 4-Cl—Ph H CH2OMe
    1-68 H Me 4-Me—Ph H CH2OH
    1-69 H Me 4-Me—Ph H CH2OMe
    1-70 H NH2 Ph H H
    1-71 H NH2 Ph H Me
    1-72 H NH2 Ph Me H
    1-73 H NH2 4-F—Ph H H
    1-74 H NH2 4-F—Ph H Me
    1-75 H NH2 4-F—Ph Cl Me
    1-76 H NH2 4-F—Ph Me H
    1-77 H NH2 4-F—Ph H Et
    1-78 H NH2 4-F—Ph H Pr
    1-79 H NH2 4-F—Ph H Bu
    1-80 H NH2 4-F—Ph H cPr
    1-81 H NH2 4-F—Ph H Ph
    1-82 H NH2 4-F—Ph H CH2Ph
    1-83 H NH2 4-F—Ph H CHF2
    1-84 H NH2 4-F—Ph H CF3
    1-85 H NH2 4-MeO—Ph H H
    1-86 H NH2 4-MeO—Ph H Me
    1-87 H NH2 4-MeO—Ph H Bu
    1-88 H NH2 4-MeO—Ph Me H
    1-89 H NH2 4-EtO—Ph H H
    1-90 H NH2 4-EtO—Ph H Me
    1-91 H NH2 4-EtO—Ph Me H
    1-92 H NH2 4-PrO—Ph H Me
    1-93 H NH2 4-MeS—Ph H H
    1-94 H NH2 4-MeS—Ph H Me
    1-95 H NH2 4-MeS—Ph Me H
    1-96 H NH2 4-Cl—Ph H H
    1-97 H NH2 4-Cl—Ph H Me
    1-98 H NH2 4-Cl—Ph Me H
    1-99 H NH2 4-Me—Ph H H
    1-100 H NH2 4-Me—Ph H Me
    1-101 H NH2 4-Me—Ph Me H
    1-102 H NH2 3-Cl-4-F—Ph H H
    1-103 H NH2 3-Cl-4-F—Ph H Me
    1-104 H NH2 3-Cl-4-F—Ph Me H
    1-105 H NH2 3,4-methylenedioxy-Ph H H
    1-106 H NH2 3,4-methylenedioxy-Ph H Me
    1-107 H NH2 3-Cl-4-MeO—Ph H H
    1-108 H NH2 3-Cl-4-MeO—Ph H Me
    1-109 H NH2 3-Cl-4-MeO—Ph Me H
    1-110 H NH2 4-CF3—Ph H H
    1-111 H NH2 4-CF3O—Ph H H
    1-112 H NH2 3-F-4-MeO—Ph H H
    1-113 H NH2 3-F-4-MeO—Ph H Me
    1-114 H NH2 3-F-4-MeO—Ph Me H
    1-115 H NH2 3-Me-4-MeO—Ph H H
    1-116 H NH2 3-Me-4-MeO—Ph H Me
    1-117 H NH2 3-Me-4-MeO—Ph Me H
    1-118 H NH2 3,4-diF—Ph H H
    1-119 H NH2 3,4-diF—Ph H Me
    1-120 H NH2 3,4-diF—Ph Me H
    1-121 H NH2 2,4-diF—Ph H H
    1-122 H NH2 2,4-diF—Ph H Me
    1-123 H NH2 2,4-diF—Ph Me H
    1-124 H NH2 3,4-diMe—Ph H H
    1-125 H NH2 3,4-diMe—Ph H Me
    1-126 H NH2 3,4-diMe—Ph Me H
    1-127 H NH2 2,4-diCl—Ph H H
    1-128 H NH2 2,4-diCl—Ph H Me
    1-129 H NH2 2,4-diCl—Ph Me H
    1-130 H NH2 3,4-diCl—Ph H H
    1-131 H NH2 3,4-diCl—Ph H Me
    1-132 H NH2 3,4-diCl—Ph Me H
    1-133 H NH2 3,4-di(MeO)—Ph H H
    1-134 H NH2 3,4-di(MeO)—Ph H Me
    1-135 H NH2 4-F—Ph H CH2OH
    1-136 H NH2 4-F—Ph H CH2OMe
    1-137 H NH2 4-MeO—Ph H CH2OH
    1-138 H NH2 4-MeO—Ph H CH2OMe
    1-139 H NH2 4-Cl—Ph H CH2OH
    1-140 H NH2 4-Cl—Ph H CH2OMe
    1-141 H NH2 4-Me—Ph H CH2OH
    1-142 H NH2 4-Me—Ph H CH2OMe
    1-143 H NH2 4-Et—Ph H H
    1-144 H NH2 4-Et—Ph H Me
    1-145 H NH2 4-Et—Ph Me H
    1-146 H NH2 2,4,6-triMe—Ph H Me
    1-147 H NH2 4-MeO—Ph Cl H
    1-148 H NH2 4-MeO—Ph Br H
    1-149 H NH2 4-MeO—Ph Cl Me
    1-150 H NH2 2-F-4-Cl—Ph H Me
    1-151 H NH2 4-EtO—Ph Cl H
    1-152 H NH2 4-MeS—Ph Cl H
    1-153 H NH2 4-MeSO—Ph H Me
    1-154 H NH2 4-EtS—Ph H Me
    1-155 H NH2 2,4-diCl—Ph Cl H
    1-156 H NH2 4-SH—Ph H Me
    1-157 H NH2 4-AcS—Ph H Me
    1-158 3-F NH2 4-MeO—Ph H Me
    1-159 3-F NH2 4-EtO—Ph H Me
    1-160 3-F NH2 3,4-diMe—Ph H Me
    1-161 3-F NH2 4-Cl—Ph H Me
    1-162 3-F NH2 4-F—Ph H Me
    1-163 3-F NH2 4-SH—Ph H Me
    1-164 3-F NH2 4-MeS—Ph H Me
    1-165 3-F NH2 4-EtS—Ph H Me
    1-166 3-F NH2 4-AcS—Ph H Me
    1-167 3-Me NH2 4-MeO—Ph H Me
    1-168 3-Me NH2 4-EtO—Ph H Me
    1-169 3-Me NH2 3,4-diMe—Ph H Me
    1-170 3-Me NH2 4-Cl—Ph H Me
    1-171 3-Me NH2 4-F—Ph H Me
    1-172 3-Me NH2 4-MeS—Ph H Me
    1-173 H NHFor 4-MeS—Ph H Me
    1-174 H NHAc 4-MeS—Ph H Me
    1-175 H NHPrn 4-MeS—Ph H Me
    1-176 H NHByr 4-MeS—Ph H Me
    1-177 H NHiByr 4-MeS—Ph H Me
    1-178 H NHVal 4-MeS—Ph H Me
    1-179 H NHiVal 4-MeS—Ph H Me
    1-180 H NHPiv 4-MeS—Ph H Me
    1-181 H NH(MeOCO) 4-MeS—Ph H Me
    1-182 H NH(EtOCO) 4-MeS—Ph H Me
    1-183 H NH(BzOCO) 4-MeS—Ph H Me
    1-184 H NH(AcOCH2) 4-MeS—Ph H Me
    1-185 H NH(PrnOCH2) 4-MeS—Ph H Me
    1-186 H NH(MeOCOOCH2) 4-MeS—Ph H Me
    1-187 H NH(EtOCOOCH2) 4-MeS—Ph H Me
    1-188 H NH[(5-Me-2-oxo-1,3- 4-MeS—Ph H Me
    dioxolen-4-yl)CH2]
    1-189 H NH[(5-Ph-2-oxo-1,3- 4-MeS—Ph H Me
    dioxolen-4-yl)CH2]
  • TABLE 2
    Cpd. No. R R1 R2 R3 R4
    2-1 H Me Ph H H
    2-2 H Me Ph H Me
    2-3 H Me 4-F—Ph H H
    2-4 H Me 4-F—Ph F H
    2-5 H Me 4-F—Ph Cl H
    2-6 H Me 4-F—Ph Br H
    2-7 H Me 4-F—Ph I H
    2-8 H Me 4-F—Ph Me H
    2-9 H Me 4-F—Ph Et H
    2-10 H Me 4-F—Ph Pr H
    2-11 H Me 4-F—Ph H Me
    2-12 H Me 4-F—Ph H Et
    2-13 H Me 4-F—Ph H Pr
    2-14 H Me 4-F—Ph H Bu
    2-15 H Me 4-F—Ph H cPr
    2-16 H Me 4-F—Ph H Ph
    2-17 H Me 4-F—Ph H CH2Ph
    2-18 H Me 4-F—Ph H CHF2
    2-19 H Me 4-F—Ph H CF3
    2-20 H Me 4-MeO—Ph H H
    2-21 H Me 4-MeO—Ph Me H
    2-22 H Me 4-MeO—Ph H Me
    2-23 H Me 4-Cl—Ph H H
    2-24 H Me 4-Cl—Ph Me H
    2-25 H Me 4-Me—Ph H H
    2-26 H Me 4-Me—Ph Me H
    2-27 H Me 4-Me—Ph H Me
    2-28 H Me 3-Cl-4-F—Ph H H
    2-29 H Me 3-Cl-4-F—Ph H Me
    2-30 H Me 3,4-Methylenedioxy-Ph H H
    2-31 H Me 3,4-Methylenedioxy-Ph H Me
    2-32 H Me 3-Cl-4-MeO—Ph H H
    2-33 H Me 3-Cl-4-MeO—Ph H Me
    2-34 H Me 4-CF3—Ph H H
    2-35 H Me 4-CF3O—Ph H H
    2-36 H Me 4-CHF2O—Ph H H
    2-37 H Me 4-CHF2O—Ph Me H
    2-38 H Me 3-F-4-MeO—Ph H H
    2-39 H Me 3-F-4-MeO—Ph H Me
    2-40 H Me 3-Me-4-MeO—Ph H H
    2-41 H Me 3-Me-4-MeO—Ph H Me
    2-42 H Me 3,4-diF—Ph H H
    2-43 H Me 3,4-diF—Ph H Me
    2-44 H Me 2,4-diF—Ph H H
    2-45 H Me 2,4-diF—Ph H Me
    2-46 H Me 3,4-diMe—Ph H H
    2-47 H Me 3,4-diCl—Ph H H
    2-48 H Me 3,4-diCl—Ph H Me
    2-49 H Me 3,4-di(MeO)—Ph H H
    2-50 H Me 3,4-di(MeO)—Ph H Me
    2-51 H Me 4-F—Ph H CH2OH
    2-52 H Me 4-F—Ph H CH2OMe
    2-53 H Me 4-MeO—Ph H CH2OH
    2-54 H Me 4-MeO—Ph H CH2OMe
    2-55 H Me 4-Cl—Ph H CH2OH
    2-56 H Me 4-Cl—Ph H CH2OMe
    2-57 H Me 4-Me—Ph H CH2OH
    2-58 H Me 4-Me—Ph H CH2OMe
    2-59 H NH2 Ph H H
    2-60 H NH2 Ph H Me
    2-61 H NH2 Ph Me H
    2-62 H NH2 4-F—Ph H H
    2-63 H NH2 4-F—Ph H Me
    2-64 H NH2 4-F—Ph Me H
    2-65 H NH2 4-F—Ph H Et
    2-66 H NH2 4-F—Ph H Pr
    2-67 H NH2 4-F—Ph H Bu
    2-68 H NH2 4-F—Ph H cPr
    2-69 H NH2 4-F—Ph H Ph
    2-70 H NH2 4-F—Ph H CH2Ph
    2-71 H NH2 4-F—Ph H CHF2
    2-72 H NH2 4-F—Ph H CF3
    2-73 H NH2 4-MeO—Ph H H
    2-74 H NH2 4-MeO—Ph H Me
    2-75 H NH2 4-MeO—Ph H Et
    2-76 H NH2 4-MeO—Ph Me H
    2-77 H NH2 4-EtO—Ph H H
    2-78 H NH2 4-EtO—Ph H Me
    2-79 H NH2 4-EtO—Ph Me H
    2-80 H NH2 4-PrO—Ph H Me
    2-81 H NH2 4-MeS—Ph H H
    2-82 H NH2 4-MeS—Ph H Me
    2-83 H NH2 4-MeS—Ph Me H
    2-84 H NH2 4-Cl—Ph H H
    2-85 H NH2 4-Cl—Ph H Me
    2-86 H NH2 4-Cl—Ph Me H
    2-87 H NH2 4-Me—Ph H H
    2-88 H NH2 4-Me—Ph Me H
    2-89 H NH2 4-Me—Ph H Me
    2-90 H NH2 4-Et—Ph H H
    2-91 H NH2 4-Et—Ph H Me
    2-92 H NH2 4-Et—Ph Me H
    2-93 H NH2 4-iPr—Ph H Me
    2-94 H NH2 3-Cl-4-F—Ph H H
    2-95 H NH2 3-Cl-4-F—Ph H Me
    2-96 H NH2 3-Cl-4-F—Ph Me H
    2-97 H NH2 3,4-Methylenedioxy-Ph H H
    2-98 H NH2 3,4-Methylenedioxy-Ph H Me
    2-99 H NH2 3-Cl-4-MeO—Ph H H
    2-100 H NH2 3-Cl-4-MeO—Ph H Me
    2-101 H NH2 3-Cl-4-MeO—Ph Me H
    2-102 H NH2 4-CF3—Ph H Me
    2-103 H NH2 4-CHF2O—Ph H Me
    2-104 H NH2 4-CF3O—Ph H Me
    2-105 H NH2 2-F-4-MeO—Ph H Me
    2-106 H NH2 3-F-4-MeO—Ph H Me
    2-107 H NH2 3-F-4-MeO—Ph Me H
    2-108 H NH2 3-Me-4-MeO—Ph H H
    2-109 H NH2 3-Me-4-MeO—Ph H Me
    2-110 H NH2 3-Me-4-MeO—Ph Me H
    2-111 H NH2 3,4-diF—Ph H H
    2-112 H NH2 3,4-diF—Ph H Me
    2-113 H NH2 3,4-diF—Ph Me H
    2-114 H NH2 2,4-diF—Ph H H
    2-115 H NH2 2,4-diF—Ph H Me
    2-116 H NH2 2,4-diF—Ph Me H
    2-117 H NH2 3,4-diMe—Ph H H
    2-118 H NH2 3,4-diMe—Ph H Me
    2-119 H NH2 3,4-diMe—Ph Me H
    2-120 H NH2 2,4-diCl—Ph H H
    2-121 H NH2 2,4-diCl—Ph H Me
    2-122 H NH2 2,4-diCl—Ph Me H
    2-123 H NH2 3,4-diCl—Ph H H
    2-124 H NH2 3,4-diCl—Ph H Me
    2-125 H NH2 3,4-diCl—Ph Me H
    2-126 H NH2 3,4-di(MeO)—Ph H H
    2-127 H NH2 3,4-di(MeO)—Ph H Me
    2-128 H NH2 4-F—Ph H CH2OH
    2-129 H NH2 4-F—Ph H CH2OMe
    2-130 H NH2 4-MeO—Ph H CH2OH
    2-131 H NH2 4-MeO—Ph H CH2OMe
    2-132 H NH2 4-Cl—Ph H CH2OH
    2-133 H NH2 4-Cl—Ph H CH2OMe
    2-134 H NH2 4-Me—Ph H CH2OH
    2-135 H NH2 4-Me—Ph H CH2OMe
    2-136 H NH2 3,5-diCl-4-MeO—Ph H Me
    2-137 H NH2 3,5-diMe-4-MeO—Ph H Me
    2-138 H NH2 2,3-diCl—Ph H Me
    2-139 H NH2 3,5-diCl—Ph H Me
    2-140 H NH2 2,4,5-triMe—Ph H Me
    2-141 H NH2 3-cPnO-4-MeO—Ph H Me
    2-142 H NH2 3-CF3-4-Cl—Ph H Me
    2-143 H NH2 3-F-4-Me—Ph H Me
    2-144 H NH2 3-Me-4-Cl—Ph H Me
    2-145 H NH2 2,4-diMe—Ph H Me
    2-146 H NH2 4-OH—Ph H Me
    2-147 H NH2 3,5-diMe—Ph H Me
    2-148 H NHAc 4-MeO—Ph H Me
    2-149 H NHAc 3,4-diMe—Ph H Me
    2-150 H NH2 4-MeO—Ph H 3-cPnO-4-MeO—Bz
    2-151 H NH2 4-MeSO—Ph H Me
    2-152 3-F NH2 4-MeO—Ph H Me
    2-153 3-F NH2 4-EtO—Ph H Me
    2-154 3-F NH2 3,4-diMe—Ph H Me
    2-155 3-F NH2 4-Cl—Ph H Me
    2-156 3-F NH2 4-F—Ph H Me
    2-157 3-F NH2 4-SH—Ph H Me
    2-158 3-F NH2 4-MeS—Ph H Me
    2-159 3-F NH2 4-EtS—Ph H Me
    2-160 3-F NH2 4-AcS—Ph H Me
    2-161 3-Me NH2 4-MeO—Ph H Me
    2-162 3-Me NH2 4-EtO—Ph H Me
    2-163 3-Me NH2 3,4-diMe—Ph H Me
    2-164 3-Me NH2 4-MeS—Ph H Me
    2-165 H NHFor 4-MeO—Ph H Me
    2-166 H NHPrn 4-MeO—Ph H Me
    2-167 H NHByr 4-MeO—Ph H Me
    2-168 H NHiByr 4-MeO—Ph H Me
    2-169 H NHVal 4-MeO—Ph H Me
    2-170 H NHiVal 4-MeO—Ph H Me
    2-171 H NHPiv 4-MeO—Ph H Me
    2-172 H NH(MeOCO) 4-MeO—Ph H Me
    2-173 H NH(EtOCO) 4-MeO—Ph H Me
    2-174 H NH(BzOCO) 4-MeO—Ph H Me
    2-175 H NH(AcOCH2) 4-MeO—Ph H Me
    2-176 H NH(PmOCH2) 4-MeO—Ph H Me
    2-177 H NH(MeOCOOCH2) 4-MeO—Ph H Me
    2-178 H NH(EtOCOOCH2) 4-MeO—Ph H Me
    2-179 H NH[(5-Me-2-oxo-1,3- 4-MeO—Ph H Me
    dioxolen-4-yl)CH2]
    2-180 H NH[(5-Ph-2-oxo-1,3- 4-MeO—Ph H Me
    dioxolen-4-yl)CH2]
    2-181 H NHFor 4-EtO—Ph H Me
    2-182 H NHAc 4-EtO—Ph H Me
    2-183 H NHPrn 4-EtO—Ph H Me
    2-184 H NHByr 4-EtO—Ph H Me
    2-185 H NHiByr 4-EtO—Ph H Me
    2-186 H NHVal 4-EtO—Ph H Me
    2-187 H NHiVal 4-EtO—Ph H Me
    2-188 H NHPiv 4-EtO—Ph H Me
    2-189 H NH(MeOCO) 4-EtO—Ph H Me
    2-190 H NH(EtOCO) 4-EtO—Ph H Me
    2-191 H NH(BzOCO) 4-EtO—Ph H Me
    2-192 H NH(AcOCH2) 4-EtO—Ph H Me
    2-193 H NH(PrnOCH2) 4-EtO—Ph H Me
    2-194 H NH(MeOCOOCH2) 4-EtO—Ph H Me
    2-195 H NH(EtOCOOCH2) 4-EtO—Ph H Me
    2-196 H NH[(5-Me-2-oxo-1,3- 4-EtO—Ph H Me
    dioxolen-4-yl)CH2]
    2-197 H NH[(5-Ph-2-oxo-1,3- 4-EtO—Ph H Me
    dioxolen-4-yl)CH2]
    2-198 H NHFor 3,4-diMe—Ph H Me
    2-199 H NHPrn 3,4-diMe—Ph H Me
    2-200 H NHByr 3,4-diMe—Ph H Me
    2-201 H NHiByr 3,4-diMe—Ph H Me
    2-202 H NHVal 3,4-diMe—Ph H Me
    2-203 H NHiVal 3,4-diMe—Ph H Me
    2-204 H NHPiv 3,4-diMe—Ph H Me
    2-205 H NH(MeOCO) 3,4-diMe—Ph H Me
    2-206 H NH(EtOCO) 3,4-diMe—Ph H Me
    2-207 H NH(BzOCO) 3,4-diMe—Ph H Me
    2-208 H NH(AcOCH2) 3,4-diMe—Ph H Me
    2-209 H NH(PmOCH2) 3,4-diMe—Ph H Me
    2-210 H NH(MeOCOOCH2) 3,4-diMe—Ph H Me
    2-211 H NH(EtOCOOCH2) 3,4-diMe—Ph H Me
    2-212 H NH[(5-Me-2-oxo-1,3- 3,4-diMe—Ph H Me
    dioxolen-4-yl)CH2]
    2-213 H NH[(5-Ph-2-oxo-1,3- 3,4-diMe—Ph H Me
    dioxolen-4-yl)CH2]
  • Of the compounds listed above, preferred compounds are:
    • 1) 3-methyl-2-(4-methylphenyl)-1-(4-sulfamoylphenyl)pyrrole,
    • 52) 4-methyl-2-(4-methylphenyl)-1-(4-sulfamoylphenyl)pyrrole,
    • 3) 1-(4-fluorophenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 4) 1-(4-fluorophenyl)-4-methyl-2-(4-sulfamoylphenyl)pyrrole,
    • 5) 5-fluoro-1-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)pyrrole,
    • 6) 2-(4-methoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 7) 1-(4-methoxyphenyl)-4-methyl-2-(4-sulfamoylphenyl)pyrrole,
    • 8) 4-ethyl-2-(4-methoxyphenyl)-1-(4-sulfamoylphenyl)pyrrole,
    • 9) 2-(4-chlorophenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 10) 4-methyl-2-(4-methylthiophenyl)-1-(4-sulfamoylphenyl)pyrrole,
    • 11) 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 12) 2-(4-methoxy-3-methylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 13) 2-(3-fluoro-4-methoxyphenyl)4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 14) 4-methyl-2-phenyl-1-(4-sulfamoylphenyl)pyrrole,
    • 15) 2-(3,4-dimethylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 16) 2-(3-chloro-4-methoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 17) 4-methyl-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 18) 5-chloro-1-(4-methoxyphenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 19) 1-(3,4-dimethylphenyl)-4-methyl-2-(4-sulfamoylphenyl)pyrrole,
    • 20) 5-chloro-1-(4-ethoxyphenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 21) 5-chloro-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 22) 1-(4-ethylthiophenyl)-4-methyl-2-(4-sulfamoylphenyl)pyrrole,
    • 23) 2-(3,5-dimethylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 24) 1-(4-mercaptophenyl)-4-methyl-2-(4-sulfamoylphenyl)pyrrole,
    • 25) 1-(4-acetylthiophenyl)-4-methyl-2-(4-sulfamoylphenyl)pyrrole,
    • 26) 1-(4-acetylaminosulfonylphenyl)-4-methyl-2-(4-methoxyphenyl)pyrrole, and
    • 27) 1-(4-acetylaminosulfonylphenyl)-4-methyl-2-(3,4-dimethylphenyl)pyrrole.
  • Of these, more preferred compounds are:
    • 2) 4-methyl-2-(4-methylphenyl)-1-(4-sulfamoylphenyl)pyrrole,
    • 6) 2-(4-methoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 9) 2-(4-chlorophenyl)4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 10) 4-methyl-2-(4-methylthiophenyl)-1-(4-sulfamoylphenyl)pyrrole,
    • 11) 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 12) 2-(4-methoxy-3-methylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 13) 2-(3-fluoro-4-methoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 15) 2-(3,4-dimethylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 17) 4-methyl-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 26)1-(4-acetylaminosulfonylphenyl)-4-methyl-2-(4-methoxyphenyl)pyrrole, and
    • 27) 1-(4-acetylaminosulfonylphenyl)-4-methyl-2-(3,4-dimethylphenyl)pyrrole.
  • Of these, the most preferred compounds are:
    • 11) 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 15) 2-(3,4-dimethylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole,
    • 17) 4-methyl-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole,
    • 26) 1-(4-acetylaminosulfonylphenyl)-4-methyl-2-(4-methoxyphenyl)pyrrole, and
    • 27) 1-(4-acetylaminosulfonylphenyl)-4-methyl-2-(3,4-dimethylphenyl)pyrrole.
  • The compounds of formula (I), compounds of formula (II) and pharmaceutically acceptable salts of these compounds are known compounds and a method of preparing these compounds is disclosed in European Patent Publication EP-799823A, the disclosure of which is incorporated herein by reference.
  • The chemical names of the compounds of formulae (III) to (XIV), respectively, are:
    • (III): 3-(3,4-difluorophenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one,
    • (IV): 4-(5-p-tolyl-3-trifluoromethyl-1H-pyrazol-1-yl)benzenesulfonamide,
    • (V): N-[6-(2,4-difluorophenylthio)-1-oxoindan-5-yl]methanesulfonamide,
    • (VI): 4-hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide,
    • (VII): N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide,
    • (VIII): 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide,
    • (IX): N-(3-formylamino-4-oxo-6-phenoxy-41′-1-benzopyran-7-yl)methanesulfonamide,
    • (X): (E)-2-ethyl-5-(3,5-di-t-butyl-4-hydroxy)benzylidene-1,2-isothiazolidine-1,1-dioxide,
    • (XI): 1-(4-methanesulfonylphenyl)-2-(4-fluorophenyl)cyclopentene,
    • (XII): 3-phenyl-4-(4-methanesulfonylphenyl)-5H-furan-2-one, and
    • (XIII): 2-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)-2-cyclopenten-1-one.
    • (XIV): 4-[5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide.
  • These compounds are disclosed in International publication number WO95/00501, J. Med. Chem., 40, 1347 (1997), International publication number WO94/13635, Pharmacology, 55, 44 (1997), Prostaglandins, 47, 55 (1994), Japanese publication number Hei 9-52882, Jpn. J. Pharmacol., 67, 305 (1995), Inflamm. Res., 47, Suppl. 3, S257 (1997), J. Med. Chem., 38, 4570 (1995), EP 863 134, U.S. Pat. No. 5,474,995 or WO 98/06708, the disclosures of which are incorporated herein by reference.
  • Since the compounds of the present invention have excellent activity for the prevention or inhibition of cachexia and very little toxicity, they are useful as preventive and therapeutic agents for cachexia. They are also useful for the treatment of tumor-related disorders, and can be used to inhibit the growth and/or metastasis of tumors.
  • Moreover, if desired, one or more of the compounds of the present invention [i.e. the compounds of formulae (I) to (XIV), inclusive] may be used in association with one or more other agents for the prevention or inhibition for tumor growth, and the compounds of the present invention and other agents may be administered simultaneously, separately or sequentially.
  • The other antitumor agent is preferably selected from a group consisting of 5-fluorouracil, cisplatin, tamoxifen, paclitaxel, docetaxel and irinotecan. Especially in the case of simultaneous administration, the compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof and the other antitumor agent may be contained in a single composition.
  • The composition of the present invention may be in any conventional form, depending on the route of administration. For example, for oral administration, it may be in the form of tablets, capsules, granules, powders or syrups. For non-oral administration it may be in the form of injections or suppositories. These formulations are prepared according to known methods and may include additives such as are well known in the art, for example excipients (e.g., organic excipients including sugar derivatives, such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives, such as corn starch, potato starch, α-starch and dextrin; cellulose derivatives, such as crystalline cellulose; gum arabic; dextran; and Pullulan, inorganic excipients including silicate derivatives, such as light silicic acid anhydride, synthetic aluminum silicate, calcium silicate and magnesium metasilicate aluminate; phosphates, such as calcium hydrogenphosphate; carbonates, such as calcium carbonate; and sulfates, such as calcium sulfate), lubricants (e.g., stearic acid and metal salts thereof, including stearic acid, calcium stearate and magnesium stearate; talc; colloidal silica; waxes, such as beeswax and spermaceti; boric acid; adipic acid; sulfates, such as sodium sulfate; glycol; fumaric acid; sodium benzoate; DL-leucine; fatty acid sodium salts; lauryl sulfates, such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids, such as silicic acid anhydride and silicic acid hydrate; and the above-mentioned starch derivatives), binders (e.g., hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, Macrogol and similar compounds to the above-mentioned excipients), disintegrating agents (e.g., cellulose derivatives, such as low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, internally bridged sodium carboxymethyl cellulose; chemically modified starch celluloses, such as carboxymethyl starch, sodium carboxymethyl starch and bridged polyvinyl pyrrolidone), stabilizers (e.g., paraoxybenzoates, such as methylparaben and propylparaben; alcohols, such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenols, such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid), corrigents (e.g., sweeteners, vinegars and perfumes) and diluents.
  • The dose varies, depending on many factors, including the condition and age of the patients, the severity and nature of the disorder and the route of administration. For example, in the case of oral administration, it is desirable to administer 0.01 mg/kg (preferably 0.1 mg/kg) as a lower limit and 50 mg/kg (preferably 10 mg/kg) as an upper limit for an adult per day, in a single dose or in divided doses, depending on the symptoms. In the case of intravenous administration, it is desirable to administer 0.001 mg/kg (preferably 0.01 mg/kg) as a lower limit and 10 mg/kg (preferably 5 mg/kg) as an upper limit for an adult, in a single dose or in divided doses, depending on the symptoms.
  • The present invention is further illustrated by the following non-limiting Examples and Formulation examples.
    • EXAMPLE 1
  • Test of Anticachexia Effects in Mice Bearing Mouse Colon Cancer Colon 26 Cells
  • The test animals were CDF1 mice (females, 8 weeks old). They were employed in groups of 10 for each test. 1×106 mouse colon cancer Colon 26 cells were transplanted subcutaneously into each animal.
  • The test compounds were Compounds No. 1-94 and 2-78 as shown above in Tables 1 and 2, respectively, and having the following formulae:
    Figure US20050004109A1-20050106-C00005
  • Each test compound was suspended in sterlized distilled water containing 0.5% w/v carboxymethyl cellulose (CMC) and administered orally once per day starting on the day of the tumor cell transplantation.
  • Each test animal was weighed immediately after tumor cell transplantation, and the weight (A g) was recorded. Each animal was then weighed on day 19 after tumor cell transplantation, and the weight (B g) was recorded. The weight gain on day 19 after tumor cell transplantation was calculated as B−A=Δgt for the test animals. The experiment was repeated with two control groups: the first control group (control group 1) was transplanted with the tumor cells but were not treated with any test compound, and the weight gain is reported as Δgc1; the second control group (control group 2) were not transplanted with the tumor cells and were not treated with any test compound, and the weight gain is reported as Δgc2. The body weight recovery rate was determined according to the following formula based on the weight gain on day 19 after tumor cell transplantation, and this value was used as an indicator of the anticachexia effect.
    Body weight recovery rate (%)=(Δg t −Δg c1)/(Δg c2 −Δg c1)×100
  • The results are shown in Table 3 below.
    TABLE 3
    Weight
    Administered Dose Gain Body Weight
    Compound (mg/kg) (Δg) Recovery Rate (%)
    Compound 2-78 10 2.6 88
    Compound 2-78 3 2.5 85
    Compound 2-78 1 2.5 85
    Compound 1-94 10 3.1 98
    Compound 1-94 3 2.7 89
    Compound 1-94 1 2.2 78
    control group 1 — −1.4 0
    control group 2 — 3.2 100
  • It is clear from the above results that these compounds inhibited mouse tumor cachexia and reduced weight loss.
    • EXAMPLE2
  • Test of Anticachexia Effects in Mice Bearing Mouse Colon Cancer Colon 26 Cells
  • The procedure described in Example 1 was repeated, but using the compound of formula (III) as the test compound, and comparing the weight gain (Δgt) of the test group of animals to which the compound of formula (III) had been administered with a control group (Δgc) into which the tumor cells had been transplanted but to which no anti-tumor compound had been administered. The test animals were female CDF1 mice, 16 weeks old. Also, the weight gain was measured 22 days after tumor transplantation. The average body weight of each group of animals immediately after tumor transplantation was 25 to 26 g. The results are shown in Table 4.
    TABLE 4
    Dose Average Weight
    Compound (mg/kg) Gain (Δg)
    Compound (III) 10  0.9
    Compound (III) 3 0.3
    Compound (III) 1 0.0
    None (Control group) — −4.2
  • It is clear from the above results that the compound of formula (III) inhibited mouse tumor cachexia and reduced weight loss.
    • EXAMPLE 3
  • Test of Anticachexia Effects in Mice Bearing Mouse Colon Cancer Colon 26 Cells
  • The procedure described in Example 2 was repeated, but using the compound of formula (IV) as the test compound, and comparing the weight gain (Δgt) of the test group of animals to which the compound of formula (IV) had been administered with a control group (Δgc) into which the tumor cells had been transplanted but to which no anti-tumor compound had been administered. The test animals were female CDF1 mice, 7 weeks old. Also, the weight gain was measured 15 days after tumor transplantation. The average body weight of each group of animals immediately after tumor transplantation was. 20 to 21 g. The results are shown in Table 5.
    TABLE 5
    Dose Average Weight
    Compound (mg/kg) Gain (Δg)
    Compound (IV) 10  −0.6
    Compound (IV) 3 −1.3
    Compound (IV) 1 −1.2
    None (Control group) — −3.4
  • It is clear from the above results that the compound of formula (IV) inhibited mouse tumor cachexia and reduced weight loss.
    • EXAMPLE 4
  • Test of Anticachexia Effects in Mice Bearing Mouse Colon Cancer Colon 26 Cells
  • Test compounds [the compounds of formula (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV)] are administered in the same manner as described in Example 2. These compounds inhibit mouse tumor cachexia and recover loss of average of body weight.
    • EXAMPLE 5
  • Life-Prolonging Activity Test
  • Observation of the mice used in Example 1 above was continued. The life-prolonging index was determined, based on the number of days each mouse survived, and this value was then used as an indicator of the life-prolonging effects of the test compounds.
  • It should be noted that, in the case of the group of mice treated with a test compound, oral administration of the respective compound once daily was continued on day 20 after tumor cell transplantation and beyond as well.
    Life-prolonging index(%)=(S t /S c−1)×100
    • St: Median value of survival time (days) of the group of mice treated with a test compound
    • Sc: Median value of survival time (days) of the control group which were not transplanted with tumor cells.
  • The results are shown in Table 6.
    TABLE 6
    Life-
    Dose Survival Period prolonging
    Compound Name (mg/kg) (median: days) Index (%)
    Compound 2-78 10 48.5 73
    Compound 2-78 3 50.5 80
    Compound 2-78 1 45.0 61
    Compound 1-94 10 45.0 61
    Compound 1-94 3 35.0 25
    Compound 1-94 1 48.5 73
    None — 28.0 0
  • As is clear from Table 6, the compounds of the present invention exhibited a prominent life-prolonging effect.
    • EXAMPLE 6
  • Life-Prolonging Activity Test
  • The experiment reported in Example 5 was repeated with the animals used in Example 2. In the case of the group of mice treated with a test compound, oral administration of the respective compound once daily was continued on day 23 after tumor cell transplantation and beyond as well. The results are shown in Table 7.
    TABLE 7
    Compound Dose Survival Period Life-prolonging
    Name (mg/kg) (median: days) Index (%)
    Compound (III) 10  43.5 91
    Compound (III) 3 37.5 63
    Compound (III) 1 40.5 76
    None — 23.0 —
    • EXAMPLE 7
  • Life-Prolonging Activity Test
  • The experiment reported in Example 5 is repeated with the animals used in Examples 3 and 4. The compounds of formulae (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV) all inhibit mouse tumor cachexia and exhibit pronounced life-prolongation.
    • EXAMPLE 8
  • Test of Concomitant use of Antitumor Agent
  • Mouse colon cancer cells are transplanted into CDF1 mice in the same manner as Example 1 followed by administration of the test compounds [Compound Nos. 2-78 and 1-94, and the compounds of formulae (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV)] and an antitumor agent (5-fluorouracil or cisplatin).
  • The concomitant use of one of the compounds of the present invention and an antitumor agent remarkably inhibits tumor growth and cachexia, to afford a pronounced life-prolonging effect.
    • EXAMPLE 9
  • Inhibitory Effect on Lung Metastasis of Mouse Malignant Melanoma B16-BL6 Cells
  • Groups of mice, each group containing ten C57BL/6 mice (female, age: 8 weeks) were transplanted intravenously into the tail vein with 3×104 of mouse malignant melanoma B16-BL6 cells.
  • The mice were, when necessary, administered intravenously into the tail vein with a bacterial lipopolysaccharide (LPS) in an amount of 3 μg each within one hour before transplantation of the melanoma cells so as to accelerate lung metastasis of the melanoma [M. J. Anasagasti et al., J. Natl. Cancer Research, 89, 645-651 (1997).]
  • As test compounds, Compound No. 2-118, a compound of formula (IV), a compound of formula (V) and indomethacin were employed, and each was suspended in sterilized distilled water containing 0.5% w/v of carboxymethyl cellulose (CMC), and the suspensions were orally administered at a dose of 1 mg/kg per day for five days starting from the day of the melanoma cell transplantation.
  • Compound No. 2-118 is 2-(3,4-dimethylphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole.
  • Inhibitory activities on lung metastasis of the melanoma cells were evaluated in terms of the lung metastasis inhibitory rate (LMI %) by counting the number of metastatic colonies in the lung on the 10th day after intravenous transplantation of the mouse malignant melanoma B16-BL6 cells at the tail.
    LMI(%)=(1−N t /N c)×100
    • Nt: Numbers of lung metastatic colonies on the 10th day in groups administered with the test compounds; and
    • Nc: Numbers of lung metastatic colonies on the 10th day in control groups which were not administered with the test compounds.
  • The results are shown in Table 8.
    TABLE 8
    LPS Dose
    Test compound administration (mg/kg) LMI (%)
    Compound 2-118 No 1 64
    Compound 2-118 Yes 1 34
    Compound (IV) Yes 1 9
    Compound (V) Yes 1 1
    Indomethacin Yes 1 −1
  • It is clear from Table 8 that the present composition was successful in inhibiting metastasis of the mouse malignant melanoma B16-BL6 cells to the lung whether or not lung metastasis was accelerated by the LPS administration (induction of inflammation reaction).
  • In particular, the present composition showed a marked inhibition of lung metastasis, while the compound of formula (IV) and the compound of formula (V), which are COX-2-selective inhibitors, and indomethacin, which is a typical NSAID, had no such inhibitory activity under the lung metastasis accelerating conditions caused by inducing inflammatory reaction (as reflecting acceleration of metastasis of tumor in a surgical operation of resecting a tumor).
    • EXAMPLE 10
  • Antitumor Effect Against Mouse Sarcoma S-180 Cells
  • 1×106 mouse sarcoma S-180 cells were transplanted subcutaneously in Balb/c nude mice (females, 8 weeks old) in groups of 10 each.
  • The test compound, Compound No. 2-118, was suspended in sterilized distilled water containing 0.5% w/v carboxymethyl cellulose (CMC) and administered orally once per day for 5 days starting on the day the tumor cells were transplanted.
  • Antitumor activity was assessed according to the following equation to determine the tumor growth inhibitory rate (GI %) on day 7 after the transplantation.
    GI(%)=(1−V t /V c)×100
    • Vt: Mean tumor volume on day 7 in a group administered test compound (*)
    • Vc: Mean tumor volume on day 7 in an untreated control group (*)
      • *: Tumor volume is defined as ½×[tumor long axis]×[tumor short axis]2
  • The results are shown in Table 9.
    TABLE 9
    Test Compound Dose (mg/kg) GI (%)
    Compound 2-118 1 54
  • It is clear from Table 9 that the composition of the present application inhibited the growth of mouse tumor cells.
    • EXAMPLE 11
  • Antitumor Effect Against Human Colon Cancer KM12-HX Cells
  • Human colon cancer KM12-HX cells were orthotopically transplanted into the cecum of nude mice according to the method of Fu et al. [X. Fu et al., Anticancer Res., 12 (1992)] using Balb/c nude mice (females, 7 weeks old) in groups of 10 each.
  • Specifically, an incision was made into the left lower abdominal region of each mouse under Abacin anesthesia, after which a thin section of tumor measuring 5 mm on a side was sutured to the cecum using absorbable surgical sutures to perform orthotopic transplant. The incision was sutured using absorbable surgical sutures and the mice were warmed and promptly awakened from anesthesia.
  • The test compound was suspended in sterilized distilled water containing 0.5% w/v carboxymethyl cellulose (CMC) and administered orally in a total of 9 doses consisting of one dose per day from days 3 to 7 after the tumor cell transplantation and from days 10 to 13 after the transplantation.
  • Antitumor activity was assessed according to the following equation to determine the tumor weight inhibitory rate (GI %) on day 14 after the transplantation.
    GI(%)=(1−V t ′/V c′)×100
    • Vt′: Mean tumor weight on day 14 in the group administered the test compound
    • Vc′: Mean tumor weight on day 14 in an untreated control group
  • The results are shown in Table 10.
    TABLE 10
    Test Compound Dose (mg/kg) GI(%)
    Compound 2-118 0.3 12
    Compound 2-118 1 35
    Compound 2-118 3 45
    Compound 2-118 10 59
  • It is clear from Table 10 that the composition of the present invention inhibited the growth of human colon cancer cells at the orthotopic transplantation site.
  • Preparation of pharmaceutical formulations containing the compounds of the present invention is further illustrated by the following non-limiting Formulation Examples.
    • FORMULATION EXAMPLE 1
  • Capsules
  • A mixture of a compound of the present invention, such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, is prepared in a digestive oily substance, such as soybean oil, cottonseed oil or olive oil, and filled into gelatin with a positive replacement pump to obtain soft capsules containing 100 mg of active ingredient. The resulting capsules are then washed and dried.
    • FORMULATION EXAMPLE 2
  • Tablets
  • Tablets are manufactured in accordance with conventional methods using 100 mg of a compound of the present invention, such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose.
  • In this case, the tablets can be coated with a preparation coating if desired.
    • FORMULATION EXAMPLE 3
  • Injections
  • 1.5% by weight of a compound of the present invention, such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, is stirred in 10% by volume of propylene glycol, and is then adjusted to a constant volume by the addition of water for injection, after which it was sterilized to prepare injections.
    • FORMULATION EXAMPLE 4
  • Suspensions
  • A suspension is produced so as to contain 100 mg of a compound of the present invention, such as the compound of formula (III), Compound No. 1-94, 2-78 or 2-118, which is ground into a fine powder, 100 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution (Japanese Pharmacopoeia) and 0.025 ml of vanillin in 5 ml of the suspension.

Claims (7)

1-67. (Canceled).
68. A method for the prevention of tumor-related disorders in a mammal in need of such prevention, which method comprises administering to said mammal an effective amount of an active compound selected from the group consisting of 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole and 4-methyl-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole.
69. The method of claim 68 for the prevention of tumor related disorders wherein the active compound is 4-methyl-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole.
70. The method of claim 68 for the prevention of tumor related disorders wherein the active compound is 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole.
71. The method of claim 68 wherein the tumor related disorder is cachexia.
72. The method of claim 71 for the prevention of cachexia wherein the active compound is 4-methyl-1-(4-methylthiophenyl)-2-(4-sulfamoylphenyl)pyrrole.
73. The method of claim 71 for the prevention of cachexia wherein the active compound is 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole.
US10/902,249 1997-12-24 2004-07-29 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia Abandoned US20050004109A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/902,249 US20050004109A1 (en) 1997-12-24 2004-07-29 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP35449997 1997-12-24
JPHEI9-354499 1997-12-24
JP1530698 1998-01-28
JPHEI10-15306 1998-01-28
JP20490798 1998-07-21
JPHEI10-204907 1998-07-21
JP26944498 1998-09-24
JPHEI10-269444 1998-09-24
US09/212,556 US6887893B1 (en) 1997-12-24 1998-12-16 Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US10/902,249 US20050004109A1 (en) 1997-12-24 2004-07-29 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/212,556 Division US6887893B1 (en) 1997-12-24 1998-12-16 Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia

Publications (1)

Publication Number Publication Date
US20050004109A1 true US20050004109A1 (en) 2005-01-06

Family

ID=27456356

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/212,556 Expired - Fee Related US6887893B1 (en) 1997-12-24 1998-12-16 Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US10/902,249 Abandoned US20050004109A1 (en) 1997-12-24 2004-07-29 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
US10/918,125 Expired - Fee Related US7745481B2 (en) 1997-12-24 2004-08-13 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/212,556 Expired - Fee Related US6887893B1 (en) 1997-12-24 1998-12-16 Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/918,125 Expired - Fee Related US7745481B2 (en) 1997-12-24 2004-08-13 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia

Country Status (22)

Country Link
US (3) US6887893B1 (en)
EP (1) EP0927555B1 (en)
KR (2) KR100432926B1 (en)
CN (1) CN1149990C (en)
AR (1) AR012272A1 (en)
AT (1) ATE527022T1 (en)
AU (1) AU745865B2 (en)
BR (1) BR9805544C1 (en)
CA (1) CA2257010C (en)
CZ (1) CZ299060B6 (en)
DK (1) DK0927555T3 (en)
ES (1) ES2372921T3 (en)
HK (1) HK1020261A1 (en)
HU (1) HU227126B1 (en)
ID (1) ID21529A (en)
IL (3) IL143921A (en)
NO (2) NO317568B1 (en)
NZ (1) NZ333399A (en)
PL (1) PL193093B1 (en)
SA (1) SA99191102B1 (en)
TR (1) TR199802676A2 (en)
TW (1) TW562675B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017024A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders
WO2009042613A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
BR9916518A (en) * 1998-12-23 2002-01-29 Searle & Co A method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and a combination comprising a cyclooxygenase-2 inhibitor and one or more antineoplastic agents.
NZ515711A (en) * 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
EP1296971A2 (en) * 2000-04-25 2003-04-02 Pharmacia Corporation 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2003020268A1 (en) * 2001-08-31 2003-03-13 Washington University Method for the treatment and prevention of cachexia
WO2003035047A2 (en) * 2001-10-25 2003-05-01 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080098491A1 (en) * 2006-10-19 2008-04-24 Zoltan Laboratories Llc Mouse models to study cachexia
US20080261961A1 (en) 2007-04-20 2008-10-23 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
US20120015919A1 (en) * 2007-09-24 2012-01-19 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
EP2224932A4 (en) * 2007-11-28 2011-09-14 Tragara Pharmaceuticals Inc Cancer treatment using cox-2 inhibitor and antimetabolite combinations
US20110301209A1 (en) * 2007-11-28 2011-12-08 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2365752B1 (en) 2008-10-29 2014-09-24 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
EP2284154A1 (en) * 2009-07-29 2011-02-16 Argon Pharma S.L. Antitumor 1,2-diphenylpyrrole compounds and their preparation process
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TW202122082A (en) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
KR20220045189A (en) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. How to treat gastrointestinal stromal tumors
BR112022013169A2 (en) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAFTIRIDIN-3-YL)-2-FLUOROFEYL)-3- PHENYLUREA
MX2022008103A (en) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof.
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962119A (en) * 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
US5208018A (en) * 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
US5317019A (en) * 1989-06-13 1994-05-31 Smithkline Beecham Corp. Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5550142A (en) * 1993-06-24 1996-08-27 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5593119A (en) * 1995-01-12 1997-01-14 At&T Global Information Solutions Company Apparatus and method for mounting a terminal
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6110948A (en) * 1996-04-04 2000-08-29 Takeda Chemical Industries, Ltd. Anticachectic composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504107A (en) 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
AU9137591A (en) 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
JPH06503349A (en) 1990-12-13 1994-04-14 スミスクライン・ビーチャム・コーポレイション New CSAIDS
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
DK0679157T3 (en) 1993-01-15 1998-07-27 Searle & Co Novel 3,4-diarylthiophenes and analogs thereof for use as anti-inflammatory agents
JP3681388B2 (en) 1993-07-13 2005-08-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Antiallergic imidazoazepine
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
CN1061036C (en) 1993-11-30 2001-01-24 G·D·瑟尔公司 Substituted pyrazolyl benzenesulfonamides for treating inflammation
HUT74986A (en) 1994-01-10 1997-03-28 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors, pharmaceutical preparations containing them, and use of them
JP3302178B2 (en) 1994-06-22 2002-07-15 日本クラウンコルク株式会社 Synthetic resin container lid
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
JP2636819B2 (en) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 Oxazole-based heterocyclic aromatic compounds
ES2183935T3 (en) 1995-02-13 2003-04-01 Searle & Co SUBSTITUTED ISOXAZOLS FOR THE TREATMENT OF INFLAMMATION.
EP0825989A1 (en) 1995-05-19 1998-03-04 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2180624C (en) 1995-07-12 2006-12-12 Cheuk Kun Lau Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ES2197983T3 (en) 1996-01-26 2004-01-16 G.D. SEARLE & CO. IMIDAZOLS REPLACED WITH HETEROCICLE FOR THE TREATMENT OF INFLAMMATION.
ES2188971T3 (en) * 1996-08-14 2003-07-01 Searle & Co CRYSTAL FORM OF THE 4- (5-METHYL-3-PHENYLISOXAZOL-4-IL) BENZENSULFONAMIDE.
WO1998016227A1 (en) 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
PL194717B1 (en) 1996-11-19 2007-06-29 Searle & Co Method of using cyclooxygenase-2 inhibitors as agents acting against overgrowth of vessels
DK0946507T3 (en) 1996-12-10 2004-01-26 Searle & Co Substituted pyrrolyl compounds for the treatment of inflammation
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962119A (en) * 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
US5317019A (en) * 1989-06-13 1994-05-31 Smithkline Beecham Corp. Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
US5208018A (en) * 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5550142A (en) * 1993-06-24 1996-08-27 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5521207A (en) * 1993-11-30 1996-05-28 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5593119A (en) * 1995-01-12 1997-01-14 At&T Global Information Solutions Company Apparatus and method for mounting a terminal
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6110948A (en) * 1996-04-04 2000-08-29 Takeda Chemical Industries, Ltd. Anticachectic composition
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6469040B2 (en) * 1997-10-14 2002-10-22 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017024A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
WO2009042613A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]

Also Published As

Publication number Publication date
AR012272A1 (en) 2000-09-27
BR9805544A (en) 2000-03-28
US20050014814A1 (en) 2005-01-20
US6887893B1 (en) 2005-05-03
CA2257010C (en) 2009-02-17
IL143921A0 (en) 2002-04-21
SA99191102B1 (en) 2006-10-11
EP0927555A1 (en) 1999-07-07
HK1020261A1 (en) 2000-04-07
NO20040145L (en) 1999-06-25
CZ299060B6 (en) 2008-04-16
TR199802676A3 (en) 1999-11-22
NO320632B1 (en) 2006-01-02
EP0927555B1 (en) 2011-10-05
IL143921A (en) 2003-11-23
ES2372921T3 (en) 2012-01-27
US7745481B2 (en) 2010-06-29
CN1230407A (en) 1999-10-06
IL127664A0 (en) 1999-10-28
AU745865B2 (en) 2002-04-11
HUP9803018A3 (en) 2000-09-28
HU227126B1 (en) 2010-07-28
NZ333399A (en) 2000-05-26
TR199802676A2 (en) 1999-11-22
CZ425898A3 (en) 1999-07-14
PL330496A1 (en) 1999-07-05
BR9805544C1 (en) 2000-06-06
TW562675B (en) 2003-11-21
KR19990063439A (en) 1999-07-26
NO986089L (en) 1999-06-25
NO986089D0 (en) 1998-12-23
KR100432926B1 (en) 2004-09-08
ATE527022T1 (en) 2011-10-15
HUP9803018A2 (en) 1999-10-28
PL193093B1 (en) 2007-01-31
DK0927555T3 (en) 2012-01-23
KR100483244B1 (en) 2005-04-15
HU9803018D0 (en) 1999-02-01
NO317568B1 (en) 2004-11-15
KR20040025927A (en) 2004-03-26
CN1149990C (en) 2004-05-19
ID21529A (en) 1999-06-24
IL127664A (en) 2003-04-10
CA2257010A1 (en) 1999-06-24
AU9822598A (en) 1999-07-15

Similar Documents

Publication Publication Date Title
US6887893B1 (en) Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
JP3034819B2 (en) 1,2-diphenylpyrrole derivative and pharmaceutical composition
AU712390B2 (en) Benzimidazole derivatives, their preparation and their therapeutic use
US7504393B2 (en) Benzylamine analogues
US20060122181A1 (en) Heteroaromatic pentacyclic compound and medicinal use thereof
US10471079B2 (en) Combination of selected analgesics and COX-II inhibitors
US20130184270A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
NO20074012L (en) 1-thio-D-glucitolderivater
JPH11246403A (en) Tumor growth prophylactic or inhibitor
JP3214695B2 (en) Prophylactic or therapeutic agent for cachexia
JPH11279078A (en) Inhibitor of cancer metastasis
JPH11180871A (en) Medicine containing 1,2-diphenylpyrrole derivative
RU2190399C2 (en) Preparation for treating and preventing cachexia
MXPA99000134A (en) Methods and compositions for the treatment and prevention of tumors, disorders related to tumors and caque
JPH0770072A (en) Thiourea derivative

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION